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The renin-angiotensin system (RAS) is a key regulator of blood pressure and electrolyte 
homeostasis. Most hemodynamic responses to angiotensin (Ang) II are mediated via 
angiotensin II type 1 receptor (AT1R). Posttranscriptional regulation is an important 
mechanism in the regulation of AT1R expression. The primary target for posttranscriptional 
regulation of AT1R is the 3’-untranslated region (UTR) of its mRNA. AT1R 3’UTR has 
multiple adenylate-uridylate-rich elements that are recognized by various RNA-binding 
proteins (RNBP). These RNBPs regulate the expression of their target mRNAs by affecting 
mRNA stability, conformation, subcellular localization, and translation.  
The aim of this study was to identify novel AT1R 3’UTR-binding RNBPs and understand 
their physiological role in AT1R function. AT1R 3’UTR-associated RNBPs were isolated 
from human vascular smooth muscle cell lysates by protein affinity purification with AT1R 
3’UTR as a probe. Mass spectrometric identification of the AT1R 3’UTR-binding proteins 
led to identification of glyceraldehyde-3-phosphate dehydrogenase (GAPDH), Hu antigen 
R (HuR) and TIA1 cytotoxic granule-associated RNA-binding protein (TIA-1).  
Oxidative stress induced by hydrogen peroxide (H2O2) increases AT1R expression. 
GAPDH was identified as a novel AT1R mRNA binding protein. GAPDH binds to a 
hairpin-structure rich in adenosine and uridine in the proximal 1-100 region of the AT1R 
3’UTR and suppresses AT1R translation. Interestingly, H2O2 promoted GAPDH 
dissociation from AT1R 3’UTR. Thus, loss of GAPDH-mediated inhibition explains 
oxidative stress-induced increase in AT1R expression. 
Insulin increases AT1R expression via posttranscriptional mechanisms. Insulin was shown 
to stabilize AT1R mRNA in a 3’UTR-dependent manner. HuR was found to bind with 
AT1R 3’UTR and stabilize AT1R mRNA. Insulin was shown to induce nucleocytoplasmic 
translocation of HuR to cytoplasm. This translocation of HuR increased HuR binding to 
AT1R 3’UTR, leading to increased AT1R expression by stabilization of AT1R mRNA. 
AT1R avoids the endoplasmic reticulum (ER) stress-mediated translational suppression. 
TIA-1 was shown to bind to the 3’UTR of AT1R mRNA and inhibit AT1R expression. 






in the cytoplasm but to dissociate from it during ER stress. The dissociated TIA-1 was 
directed to translationally-silenced stress granules (SG), while AT1R mRNA remained 
excluded from them. Thus, AT1R mRNA avoids aggregation to SGs and TIA-1-mediated 
translational suppression during ER stress. 
In conclusion, the 3’UTR of AT1R mRNA mediates the regulation of AT1R expression by 
oxidative stress, insulin stimulation, and ER stress. AT1R expression is modified by altered 







Angiotensin (Ang) II is a central component of the renin-angiotensin system (RAS) that 
regulates blood pressure, electrolyte and body fluid homeostasis, as well as cardiovascular 
structure. Most of the deleterious effects of Ang II, including elevated blood pressure, 
production of reactive oxygen species and activation of pro-inflammatory pathways, are 
mediated by angiotensin II type 1 receptor (AT1R) (Touyz and Schiffrin 2000, Dinh et al. 
2001, Mehta and Griendling 2007, Higuchi et al. 2007). The type 2 receptor expression is 
much more restricted and usually has counteracting effects on AT1R (Horiuchi et al. 1999, 
Dinh et al. 2001). Cardiovascular diseases (CVD) combined constitute the leading cause of 
death and disability globally (www.who.int/en/). The important role of AT1R in 
development of CVDs is supported by the beneficial effects obtained by pharmacological 
inhibition of AT1R function (Oparil et al. 2001, PROGRESS Collaborative Group 2001, 
Gradman et al. 2005). 
AT1R expression is regulated at multiple levels from transcription to translation. A number 
of physiological factors have been found to regulate AT1R expression via a 
posttranscriptional mechanism. Growth factors (Nickenig and Murphy 1994), Ang II 
(Nickenig and Murphy 1996), and estrogen (Wu et al. 2003) have been established as 
negative, whereas low-density lipoprotein (LDL) (Nickenig et al. 1997) and insulin 
(Nickenig et al. 1998) as positive regulators of AT1R expression in a posttranscriptional 
manner. Thyroid hormone mediates posttranscriptionally both positive and negative effects 
on AT1R expression, depending on cell type (Fukuyama et al. 2003, Diniz et al. 2012). 
RNA-binding proteins (RNBP) identified to posttranscriptionally regulate AT1R expression 
via the 3’-untranslated region (UTR) of AT1R mRNA include AU-rich element RNA-
binding protein 1, 37kDa (AUF1) (Pende et al. 1999), calreticulin (Nickenig et al 2002, 
Mueller et al. 2008), and P100 (Paukku et al. 2008). Apart from Ang II-mediated 
posttranscriptional regulation of AT1R expression by AUF1 (Pende et al. 1999) and 
calreticulin (Nickenig et al. 2002, Mueller 2008), detailed molecular mechanisms of AT1R 
posttranscriptional regulation remain poorly understood.  
Comprehensive understanding of regulation of AT1R expression may provide new 






AT1R expression in more detail at the level of molecular mechanisms. The aim was to 
identify novel AT1R 3’UTR-associated RNBPs, describe their effect on AT1R mRNA 
dynamics and AT1R expression, and to define the physiological factors and mechanisms 






REVIEW OF THE LITERATURE 
1. Pathogenesis of hypertension and atherosclerosis 
Cardiovascular diseases (CVD) such as hypertension, atherosclerosis, coronary heart 
disease, heart failure, cerebrovascular disease, and peripheral artery disease constitute the 
leading cause of death and disability globally. It has been estimated that in 2012 around 
17.5 million people died from CVDs and according to a global status report by the World 
Health Organization, 9.4 million deaths could be attributed to high blood pressure in 2010 
(www.who.int/en/). The present day global obesity epidemic further worsens these 
numbers. 
1.1. Pathogenesis of hypertension 
According to the European Society of Hypertension (ESH) and European Society of 
Cardiology (ESC) guidelines, the clinical classification of hypertension is a condition where 
blood pressure (BP) is continuously 140/90 mmHg or higher (http://www.escardio.org/). 
Hypertension can be divided into two categories, primary or secondary. The majority of 
cases, around 95 %, are classified as primary hypertension where there is no obvious 
underlying medical cause (Carretero and Oparil 2000). Secondary hypertension is caused 
by an underlying condition such as the presence of renovascular disease or a tumor-secreting 
blood-pressure-elevating hormones (Chiong et al. 2008).  
Primary hypertension is a multifactorial condition where both genetic and environmental 
factors influence the development of hypertension. While no single genetic defect has been 
found to be the cause of primary hypertension, the genetic impact on BP varies greatly. In 
a study by Kupper et al. (2005) the heritability of BP was calculated to be 32-57% for 
systolic and 31-63% for diastolic, depending on the evaluation criteria. In addition to genetic 
predisposition, environmental factors play a significant role in the development of 
hypertension. The major environmental risk factors for hypertension include high alcohol 
consumption, diminished aerobic physical exercise, and unhealthy diet such as excess use 






The first steps in prevention or treatment of hypertension involve lifestyle changes and if 
this is not enough, pharmacological intervention may be applied. The main classes of anti-
hypertensive drugs, according to the ESH and ESC guidelines, include beta-blockers, 
diuretics, calcium (Ca2+) antagonists, angiotensin converting enzyme (ACE) inhibitors, 
angiotensin II receptor blockers (ARB), renin inhibitors, and mineralocorticoid receptor 
antagonists (http://www.escardio.org/). Of these, ARBs directly inhibit AT1R activation 
whereas inhibitors of renin and ACE prevent Ang II production and thus indirectly inhibit 
AT1R functions. 
1.2. Pathogenesis of atherosclerosis 
Atherosclerosis is characterized by the formation of atheromatous plaques in the tunica 
intima of the arteries, leading to the thickening and stiffening of the arterial wall. The 
growing plaques may cause stenosis that reduces blood flow, leading to ischemia. Rupture 
of the plaques in turn may cause myocardial infarction or stroke via thrombosis i.e. the 
formation of a blood clot. A thrombus may block the artery, resulting in the restriction of 
blood flow at the site of the rupture or, if dislodged, in distal arteries. Extensive studies to 
unravel the pathophysiological mechanisms of atherosclerosis have revealed it as a 
multifactorial and complex disease. While a great deal has been learned from various animal 
models and cell culture experiments, the pathophysiological mechanisms in humans are still 
largely unknown. What is known is that the progression of atherosclerosis takes decades 
and involves a complex interplay between extra- and intracellular lipid metabolism, 
inflammatory processes, endothelial dysfunction, and immunological responses (Lusis 
2000, Libby et al. 2011, Weber and Noels 2011) 
As stated by the response to retention model, subendothelial accumulation of apolipoprotein 
B-containing lipoproteins, including low-density lipoprotein (LDL) and apolipoprotein B 
remnants, and resulting inflammation are considered as key initiators of atherogenesis, i.e. 
the formation of the plaques (Williams and Tabas 1995, Tabas et al. 2007). There are, in 
addition, other pathways connected to the initiation of atherogenesis. According to the 
response to injury model, atherogenesis is initiated by physical injury of the endothelial 
layer of the vascular wall, thus promoting the adhesion of leukocytes and production of pro-






plaques show no evidence of physical injury of the endothelial layer, this triggering pathway 
was later modified suggesting that the endothelial dysfunction may act as an enhancer of 
atherogenesis by increasing the endothelial permeability to lipoproteins (Ross 1999, 
Gimbrone 1999). The second pathway connected to initiation of atherosclerosis, known as 
the oxidative modification hypothesis, underlines the importance of oxidatively modified 
lipoproteins such as oxidized LDL (oxLDL) in the progression of atherogenesis. This is 
supported by the findings that oxidative modification of LDL, taking place primarily in the 
tunica intima, promotes its uptake by macrophages via their scavenger receptors and is 
required for many of the pro-atherogenic functions of LDL (Steinberg et al. 1989, Diaz et 
al. 1997).  
While the key triggering mechanisms of atherogenesis or their combinations are under 
extensive research and discussion, the subsequent consequences follow the same scheme. 
One of the first steps in atherogenesis is characterized by the adhesion of circulating 
leukocytes, mainly monocytes, to the endothelial cells lining the inner wall of the arteries 
(Figure 1 A-B) (Gerrity 1981). In response to atherogenic stimuli, vascular cells release 
chemoattractant cytokines (Moore and Tabas 2011, Drechsler et al. 2015) and the 
endothelial cells begin to express adhesion molecules, such as vascular cell adhesion 
molecule-1 (VCAM-1), on their surface (O’Brien et al. 1993, Cybulsky et al. 2001, Galkina 
and Ley 2007). Leukocytes that are guided to the site by chemotaxis attach to the adhesion 
molecules, roll on the endothelial surface and finally migrate across the endothelial 
monolayer to the underlying tunica intima. When resident in the intima, monocytes, a subset 
of leukocytes, differentiate into macrophages that engulf modified lipoproteins, including 
oxLDL or enzymatically modified LDL, transforming them into lipid-loaded foam cells that 
serve as an important source of lipid (mostly cholesterol ester) and cell debris accumulation 
in the developing plaque (Figure 1B) (Gerrity 1981, Bentzon et al. 2014). 
Another important step in the initiation of atherogenesis is the infiltration of vascular smooth 
muscle cells (VSMC) from tunica media to tunica intima. When resident in the intima, the 
VSMCs proliferate and secrete collagen and elastin. These extracellular matrix components 
produce a structure known as a fibrous cap that covers and stabilizes the developing plaque 
(Figure 1 C) (Libby et al. 2011). Dying cells, such as VSMCs and foam cells, under the 






crystals at the central part of the developing plaque, forming a structure known as the 
necrotic core (Libby et al. 2011, Bentzon et al. 2014). 
Ultimately, disruption of the fibrous cap leads to plaque rupture (Figure 1 D). One of the 
key features rendering the plaque susceptible to rupture is the thinning of the fibrous cap. 
This is thought to be due to decreased matrix formation, especially reduced collagen content, 
as a response to increased apoptosis of the plaque resident VSMCs and macrophage-induced 
proteolytic degradation of the matrix components (Bentzon et al. 2014). Fractured plaque 
exposes pro-coagulant material of the plaque core to coagulants in the blood, leading to the 
formation of the thrombus that is responsible for the ultimate pathological consequences of 
atherosclerosis. 
 
Figure 1. Atherogenesis. Adapted from Libby et al. 2011. 
2. Regulation of gene expression at mRNA level 
Cells regulate the expression of their genes in order to keep up normal physiological 
functions as well as to adapt to environmental changes. Gene expression is regulated at 
several different levels. Everything from the speed of transcription to the decay rate of the 
mRNA molecule are under strict control. The pre-mRNA molecules undergo extensive 






splicing of introns and exons before being transported from the nucleus to the cytoplasm 
where they are taken up by the translational machinery (Proudfoot et al. 2002). In addition 
to these classical processes, there are several other regulatory steps between transcription 
and decay that are collectively referred to as posttranscriptional regulation. 
2.1. mRNA structure and cis-acting elements 
The three dimensional structure of an mRNA molecule is significantly more complex and 
versatile compared to a DNA molecule. The backbone of an RNA molecule consists of a 
phosphate group and a ribose sugar unlike the deoxyribose sugar in DNA molecules. 
Because RNA, unlike DNA, does not form double helix by pairing with a complementary 
RNA molecule, they can form different types of secondary structures within a single 
molecule. The secondary structures, such as hairpins and loops, are usually formed between 
complementary sequences within the mRNA by canonical Watson-Crick basepairing where 
cytosine and uracil pair up with guanine and adenine, respectively (Watson and Crick 1953). 
These structures play an important role in the regulation of RNA function. They may act as 
targets for various trans-acting factors such as RNA-binding proteins (RNBP) that have 
multiple roles in the posttranscriptional processes of mRNA molecules.  
As a rule, mRNA structure can be divided into five different segments in 5’-3’ order: 5’cap, 
5’-untranslated region (UTR), protein coding sequence (CDS), 3’UTR and the poly-A tail 
(Figure 2). The 5’-end of the transcript contains the 5’cap structure, the role of which is to 
guide the assembly of the translational machinery and protection of the mRNA transcript 
from exonuclease-mediated decay (Proudfoot et al. 2002). Following the cap, there is the 
5’UTR that may regulate translational efficiency via various cis-acting elements such as 
internal ribosomal entry sites (IRES), which function in the cap-independent translation 
under situations like cellular stress when cap-dependent translation is halted (Kullmann et 
al. 2002, Holcik and Sonenberg 2005, Thakor and Holcik 2012). The presence of out-of-
frame upstream open reading frames (uORF) allow the translation to initiate from an 
alternative site, thus competing with the translation from the actual start codon and resulting 
in reduced protein expression (Morris and Geballe 2000, Meijer and Thomas 2002, Calvo 
et al. 2009). When in-frame with the actual coding sequence, they may also produce 







Figure 2. Structure of an mRNA molecule and its trans-acting factors. Adapted from Mignone et 
al. 2002. 
The coding sequence located between the 5’ and 3’UTR acts as a template for the encoded 
protein. The content of the coding sequence can be regulated via a process known as 
alternative splicing that can alter the actual polypeptide encoded by the mRNA. Following 
the coding sequence is the 3’UTR that is considered to be the major posttranscriptional 
regulatory element. While not being translated, this element functions as the target site for 
various regulatory mediators affecting the mRNA stability, conformation, nuclear export, 
translation, and localization. The cis-acting elements in the 3’UTR are specific sequences 
and structures that serve as targets for a variety of trans-acting factors such as RNBPs and 








Table 1. Cis-acting elements in 3’UTRs 
CIS-acting element Function Example mRNA Reference 
AU-rich element (ARE) Translation, stability AT1R Pende et al. 1999 
GU-rich element (GRE) Stability c-jun Vlasova et al. 2008 
CU-rich element 
(CURE/DICE) Translation, stability 
MAP3K7IP2, 
r15-LOX 
Wang et al. 2006,  
Messias et al. 2006 
CA-rich element (CARE) Splicing, stability bcl-2, eNOS Hui et al. 2003 Lee et al. 2009,  
Iron responsive element (IRE) Translation, stability TfR Casey et al. 1989 
Selenocysteine insertion 
sequence (SECIS) UGA to selenocysteine GPx Gromer et al. 2005 
AT1R = angiotensin II type 1 receptor; AU = adenylate-uridylate; bcl-2 = B-cell CLL/lymphoma 2; CA = 
cytidylate-adenylate; c-jun = jun proto-oncogene; CU = cytidylate-uridylate; eNOS = endothelial nitric oxide 
synthase; GPx = Glutathione peroxidase; GU = guanylate-uridylate; MAP3K7IP2 = TGF-beta activated kinase 
1/MAP3K7 binding protein 2; r15-LOX = reticulocyte 15-lipoxygenase; TfR = transferrin receptor. 
The poly-A tail at the end of the transcript is added in a process known as polyadenylation, 
orchestrated by a multi-protein 3’-processing complex (Colgan and Manley 1997). The 
length of the poly-A tail can vary significantly but in mammals it is usually around 250 
nucleotides (nt) in size (Kühn et al. 2009). In addition to protecting the transcript from 
exonuclease activity, the poly-A tail takes part in nuclear export of the molecule and in its 
translational regulation (Millevoi and Vagner 2010, Matoulkova et al. 2012). Genes may 
also contain more than one polyadenylation signal that may result in changes in the coding 
sequence or more commonly in the 3’UTR length of the transcripts by alternative 
polyadenylation (Tian et al. 2005, Elkon et al. 2013). This may have a significant effect on 
the 3’UTR-mediated regulatory mechanisms of the mRNA. For example, the genes 
encoding for Hu antigen R (HuR) (Al-Ahmadi et al. 2009) and cyclooxygenase 2 (Cox-2) 
(Hall-Pogar et al. 2005) contain alternative poly-A sites that result in variation of their 3UTR 
lengths and inclusion or exclusion of different 3’UTR-located adenylate-uridylate (AU) -






2.2 AU-rich elements 
The best characterized group of cis-acting elements in the 3’UTRs are the AREs. The 
current estimates for ARE-containing human genes vary between 5% and 16% (Bakheet et 
al. 2006, Gruber et al. 2011). AREs are usually described as destabilizing elements that 
promote decay of the mRNA molecule. However, depending on their associated trans-
acting factors, they can lead to stabilization of the transcript as well (Lal et al. 2004, Barreau 
et al. 2006). 
The core sequence of this element is AUUUA, but the classification is further divided into 
sub-categories depending on the more specified nucleotide sequence. The basic model from 
Chen and Shyu (Chen and Shyu 1994, Chen and Shyu 1995) divides AREs in three classes 
based on the variation of the core sequence. Class I AREs contain the classic AUUUA 
sequence in 1 to 3 copies within a uridylate-rich region, whereas the class II AREs consist 
of at least two overlapping UUAUUUA(U/A)(U/A) sequences. The class III AREs are not 
that well defined and can consist of uridylate rich regions lacking the AUUUA sequence. 
More detailed classifications, such as the one used by the ARE database, ARED 
(http://brp.kfshrc.edu.sa/ARED/) uses the classification of Chen and Shyu as the basis but 
divides the class II further depending on the number of the AUUUA repeats and their 
surrounding sequences (Bakheet et al. 2001, Barreau et al. 2006) 
2.3 mRNA trans-acting factors 
Multiple aspects of mRNA processing, such as nuclear export, posttranscriptional 
processing, subcellular localization, translation, and half-life are regulated by trans-acting 
factors like RNBPs that recognize their target mRNAs cis-acting elements via RNA-binding 
domains. The RNA-binding domains of different RNBPs consist of a variety of elements 
that are shared between the proteins, but each RNBP has its own combination of them. This 
facilitates the diverse functions and specificity of different RNBPs (Glisovic et al. 2008). 
One of the most abundant and widely studied domains is the RNA recognition motif (RRM), 
proposed to be present in up to 1% of human genes (Lunde et al. 2007). In addition, there 
are some unconventional protein domains that have been shown to possess RNA-binding 






structure is the NAD+-binding domain of glyceraldehyde-3-phosphate dehydrogenase 
(GAPDH) that has been shown to bind AREs (Nagy and Rigby 1995, Nagy et al. 2000) 
AREs are targets for a group of proteins called ARE-binding proteins (ARE-BP). They are 
a diverse group of proteins with multiple functions. They can either stabilize or destabilize 
the target mRNA as well as affect their translational efficiency. The effect of AREs on the 
mRNA depends on their associated ARE-BPs (Barreau et al. 2006). Some of the 
characterized ARE-BPs and their RNA-binding domains are listed in table 2.  
ARE-BPs with opposite effects often compete for the same target mRNAs and one or the 
other is preferred, depending on environmental factors. For example, AUF1 and HuR both 
bind to the mRNA encoding for cyclin D1. HuR stabilizes the mRNA whilst AUF1 
promotes its rapid degradation (Lal et al. 2004). HuR also competes with CELF2 (also 
known as CUGBP2) for binding to the 3’UTR of Cox-2 mRNA. Here, both HuR and CELF2 
stabilize the mRNA, and while HuR enhances the translation, CELF2 has the opposite effect 
(Sureban et al. 2007). Cytochrome C expression is, in turn, regulated by HuR and TIA1 
cytotoxic granule-associated RNA-binding protein (TIA-1) via 3’UTR-dependent 
translational control. While neither HuR nor TIA-1 affect cytochrome C mRNA stability, 
HuR promotes and TIA-1 inhibits its translation (Kawai et al. 2006). 
In the coming sections only those ARE-BPs that are essential for the present thesis, i.e. 







Table 2. Partial list of known ARE-BPs 
ARE-BP RNA-binding domains Target example Reference 
AUF1 RNA recognition motif (RRM) x2 IL-6 Paschoud et al. 2006 
CELF2 RRM x3 Cox-2 Mukhopadhyay et al. 2003 
GAPDH NAD+-binding domain Cox-2 Ikeda et al. 2012 
hnRNP A1 RRM x2 cIAP1 Zhao et al.  2009 
hnRNP A2 RRM x2 Glut 1 Hamilton et al. 1999 
hnRNP L RRM x2 Glut 1 Hamilton et al. 1999 
Hsp70 ATP- and peptide-binding domains Cox-2, VEGF Kishor et al. 2013 
HuR RRM x3 Cox-2 Doller et al. 2008 
KHSRP K homology domain (KH) x4 LDLR Li et al. 2009 
Nucleolin RRM x4 bcl-2 Sengupta et al. 2004 
PTBP1 RRM x4 LDLR Li et al. 2009 
RNPC1 RRM x1 MIC-1 Yin et al. 2013 
TIA-1 RRM x3 Cox-2 Dixon et al. 2003 
TIAR RRM x3 BRCA1 Podszywalow-Bartnicka et al. 2014 
TTP Zinc finger (Znf) CCCH-type x2 TNF  Carballo et al. 1998 
YBX1 Cold shock domain (CSD) x1 GM-CSF Capowski et al. 2001 
AUF1 = AU-rich element RNA-binding protein 1, 37kDa; bcl-2 = B-cell CLL/lymphoma 2; BRCA1 = breast 
cancer 1; CELF2 = CUGBP, Elav-like family member 2; cIAP1 = baculoviral IAP repeat containing 2; Cox-
2 = cyclooxygenase 2; GAPDH = glyceraldehyde-3-phosphate dehydrogenase; Glut-1 = glucose transporter 
1; GM-CSF = granulocyte-macrophage colony-stimulating factor; hnRNP A1 = heterogeneous nuclear 
ribonucleoprotein A1; hnRNP A2 = heterogeneous nuclear ribonucleoprotein A2/B1; hnRNP L = 
heterogeneous nuclear ribonucleoprotein L; Hsp70 = heat shock 70kDa protein 1A, HuR = Hu antigen R; IL-
6 = interleukin 6, KHSRP = KH-type splicing regulatory protein; LDLR = low density lipoprotein receptor; 
MIC-1 = macrophage inhibitory cytokine-1; TIA-1 = TIA1 cytotoxic granule-associated RNA-binding 
protein; TIAR = TIA1 cytotoxic granule-associated RNA-binding protein-like 1; TNF  = tumor necrosis 
factor ; TTP = tristetraprolin; PTBP1 = polypyrimidine tract binding protein 1; VEGF = vascular endothelial 
growth factor; YBX1 = Y box binding protein 1; RNPC1 = RNA binding motif protein 38. The RNA-binding 









Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) is best known for its role in 
glycolysis where it catalyzes the conversion of glyceraldehyde 3-phosphate (G3P) to 1,3-
bisphosphoglycerate (1,3BPG) in a reaction that reduces nicotinamide adenine dinucleotide 
(NAD) from its oxidized form, NAD+ to NADH. GAPDH is a multifunctional protein that 
takes part in several cellular processes (Nicholls et al. 2012). GAPDH localizes to the 
nucleus where it protects the cells from telomere shortening (Sundararaj et al. 2004, 
Demarse et al. 2009) and promotes apoptosis (Dastoor and Dreyer 2001, Hara et al. 2005, 
You et al. 2013). GAPDH also functions as a transcriptional regulator (Zheng et al. 2003, 
Harada et al. 2007) and interacts with other proteins, for example in regulation of protein 
transport from endoplasmic reticulum to Golgi (Tisdale 2001, Tisdale et al. 2004). 
One of the best characterized extraglycolytic activities of GAPDH is its role as an RNBP. 
GAPDH binding to its target mRNAs is mediated by its NAD+-binding domain and the 
GAPDH-RNA interaction may be competed and even inhibited by NAD+, NADH, or ATP 
(Nagy and Rigby 1995, Nagy et al. 2000). Both connective tissue growth factor (CTGF) and 
Cox-2 mRNAs are targets of GAPDH; this interaction is inhibited by NAD+ (Kondo et al. 
2011, Ikeda et al. 2012). Kondo et al. also described the CTGF mRNA-GAPDH interaction 
to be decreased by an oxidative agent, diamide, thus suggesting a redox sensitive regulation 
of GAPDH binding to RNA (Kondo et al. 2011). This is further supported by redox-
sensitive, 3’UTR-mediated regulation of endothelin-1 by GAPDH (Rodriguez-Pascual et al. 
2008). Under normal conditions GAPDH acts as a negative regulator of endothelin-1 
expression via increasing its mRNA decay. The active site of GAPDH is needed for RNA 
binding as both NAD+ and G3P are capable of inhibiting the GAPDH-RNA interaction. 
Further, the catalytic cysteine residue at the active site of GAPDH regulates its redox-
sensitive RNA-binding capability. Exposure of the wild type GAPDH to oxidative agents 
leads to modification of the active-site cysteine and inhibition of GAPDH-RNA interaction. 
Mutation of the GAPDH active-site cysteine to a serine fails to significantly affect the 
protein structure or the RNA binding capability but prevents the cysteine-targeted oxidative 
modifications. This mutated GAPDH retains its RNA-binding capability and suppressive 






the active-site cysteine is regulating the redox-sensitive binding of GAPDH to RNAs 
(Rodriguez-Pascual et al. 2008). 
2.3.2. HuR 
Hu antigen R (HuR), also known as ELAV like RNA binding protein 1 (ELAVL1), belongs 
to a protein family of Hu-proteins consisting of three other family members, HuB, HuC, and 
HuD (Hinman and Lou 2008). HuR is a ubiquitously expressed protein that was first 
characterized and mapped by Ma et al. (Ma et al. 1996, Ma and Furneaux 1997). HuR 
consists of three RNA recognition motifs (RRM) RRM1, RRM2, and RRM3. RRM2 and 
RRM3 are separated by a hinge region that contains the HuR nucleocytoplasmic shuttling 
sequence (Fan and Steitz 1998a). RRM1 and RRM2 are thought to mediate RNA-binding, 
whereas RRM3 stabilizes protein-protein interactions and binds to the poly-A tail of 
mRNAs. HuR is primarily nuclear but upon various stimulations shuttles to the cytoplasm 
where it binds to its target mRNAs (Doller et al. 2008). HuR was originally described as an 
mRNA stabilizing factor that protects VEGF (Levy et al. 1998) and c-fos (Fan and Steitz 
1998b, Peng et al. 1998) mRNAs from decay. Later, HuR was shown to stabilize a number 
of other ARE-containing mRNAs, including those for tumor necrosis factor  (TNF ) (Dean 
et al. 2001) and Cox-2 (Sengupta et al. 2003). In addition to promoting mRNA stability, 
HuR regulates alternative splicing (Izquierdo 2008, Zhao et al. 2014) and translation 
(Mazan-Mamczarz et al. 2003, Meng et al. 2005, Kawai et al. 2006). The detailed 
mechanisms by which HuR acts as a positive regulator of its target mRNAs is somewhat 
unclear but it has been suggested to involve regulation of polyadenylation (Dai et al. 2012), 
polysomal targeting (Doller et al. 2013), and competition with destabilizing factors (Linker 
et al. 2005, Sureban et al. 2007, Tiedje et al. 2012, Zhuang et al. 2013). 
2.3.3. TIA-1 
TIA1 cytotoxic granule-associated RNA-binding protein (TIA-1) was first characterized as 
a granule-associated protein in cytolytic lymphocytes and was originally designated as T-
cell restricted intracellular antigen-1. It was identified to be expressed as two isoforms called 
p40-TIA-1 and p15-TIA-1 (Anderson et al. 1990, Tian et al. 1991, Kawakami et al. 1994). 






thus renamed as Granule Membrane Protein of 17 kDa (GMP-17), while the name TIA-1 
was reserved for the p40 isoform (Medley et al. 1996). The gene encoding TIA-1 consists 
of 13 exons and there are two splice variants: TIA-1a that lacks exon 5 and TIA-1b where 
the exon 5 is included. Little is known about the functional differences between these two 
variants. They have been shown to exhibit differential tissue expression, and TIA-1b 
appears to have enhanced splicing activity over TIA-1a (Kawakami et al. 1994, Izquierdo 
and Valcárcel 2007). 
In addition to its role in splicing, TIA-1 is associated with other cellular processes, including 
induction of apoptosis (Tian et al. 1991) and translational suppression (Dixon et al. 2003, 
Kawai et al. 2006). One of the best characterized functions of TIA-1 is its role in stress 
granule (SG) assembly in unfolded protein response (UPR) (Kedersha et al. 1999). TIA-1 
is most abundantly found in the nucleus but constantly shuttles between the nucleus and 
cytoplasm (Zhang et al. 2005). 
TIA-1 consists of three RRMs and a glutamine-rich C-terminal domain. The prion-related 
domain (PRD) in the C-terminus is needed for the aggregation of TIA-1 during SG assembly 
(Gilks et al. 2004). The three RRMs show distinct RNA-binding capabilities. The C-
terminal RRM2 and RRM3 are needed for TIA-1 to bind uridine-rich sequences, where 
RRM3 is not required for the binding but stabilizes the interaction (Dember et al. 1996). 
The N-terminal RRM1 expresses no significant RNA-binding capability without the 
presence of the other RRMs. However, it has been shown to enhance the C-terminal domain-
mediated protein-protein interaction between TIA-1 and U1-C protein of the U1 small 
nuclear ribonucleoprotein (Dember et al. 1996, Förch et al. 2002). 
3. Cellular stress and the unfolded protein response 
Cells are sensitive to different environmental changes and usually respond to them by 
adapting their metabolism accordingly. Nevertheless, sometimes the changes are too big or 
too long for the cells to cope with, leading to cellular stress. Oxidative stress, metabolic 
stress, and inflammation are common stressors that the cells are exposed to under various 
environmental conditions. The common denominator for all of them is the induction of 






3.1. The unfolded protein response 
Endoplasmic reticulum is the site of synthesis for secretory and membrane-bound proteins 
of the cell surface and intracellular compartments. In addition, it also participates in lipid 
metabolism, Ca2+ storage, and carbohydrate synthesis (Halperin et al. 2014). A situation 
where the homeostasis of the ER is compromised is known as ER stress. ER stress leads to 
the accumulation of unfolded proteins in the ER lumen and dissociation of an ER chaperone 
glucose-regulated protein 78 kDa (GRP78) from the luminal, N-terminal parts of three 
distinct ER transmembrane sensors: protein kinase RNA-like ER kinase (PERK), inositol-
requiring protein 1  (IRE1 ) and activating transcription factor 6 (ATF6) (Figure 3). 
Dissociation of GRP78 from these sensors leads to their activation and to induction of UPR 
pathways to cope with and to overcome the unfolded protein load in the ER (Hetz 2012). 
 






Activation of IRE1  and ATF6 leads to activation of transcription factors upregulating the 
expression of various UPR genes. Activated PERK phosphorylates eukaryotic translation 
initiation factor 2  (eIF2 ) leading to accumulation of non-functional translation initiation 
complexes. This inhibits the cap-dependent translation of new proteins, thus reducing the 
unfolded protein load in the ER. (Hetz 2012). Another consequence of eIF2  
phosphorylation is the subsequent formation of SGs. These are macromolecular 
ribonucleoprotein-complexes consisting of polyadenylated mRNAs and proteins. The main 
function of these structures is to sequester mRNAs into translationally-silenced foci during 
cellular stress while protecting them from decay (Anderson and Kedersha 2009, Adjibade 
and Mazroui 2014). 
3.2. Physiological stressors 
Oxidative stress 
Oxidative stress is a situation where the formation of reactive oxygen species (ROS) exceeds 
the capacity of the cells to neutralize them. ROS are needed for normal cellular signaling 
(Suzuki et al. 1997), but their excessive production has damaging effects on cells by 
oxidation of lipids, proteins, and nucleic acids, as well as by inactivating nitric oxide (NO). 
Some of the key sources for ROS within vascular cells are presented in Figure 4. NADPH 
oxidases (NOX) and xanthine oxidases, expressed in the cells at the vascular wall, are 
important sources of superoxide anion (O2-) and hydrogen peroxide (H2O2) (Berry et al. 
2000, Kelley et al. 2010). O2- reacts with the potent vasodilator NO, converting it to 
peroxynitrite (ONOO-), a strong oxidant that has been suggested to promote atherogenesis 
in vivo by increasing LDL oxidation (Leeuwenburgh et al. 1997). During oxidative stress, 
uncoupling of the endothelial nitric oxide synthase (eNOS) may further reduce NO 
bioavailability. Uncoupling of eNOS switches its function from NO production to 
production of O2- (Münzel et al. 2005). This further increases the ROS load in the cell. 
While H2O2 alone is a relatively weak oxidant, it can promote the formation of hydroxyl 
radicals (OH•) by reacting with O2- or via a Fenton reaction where it oxidizes ferrous (Fe2+) 







Figure 4. Production of ROS in the vasculature. 
Normally antioxidants, including vitamin E and C or various enzymes, including superoxide 
dismutases, catalase, glutathione peroxidase, and peroxiredoxins are capable of 
circumventing the deleterious effects of ROS by neutralizing them. Superoxide dismutases 
catalyze the conversion of O2- to oxygen (O2) and H2O2, which is further processed via 
catalase, glutathione peroxidase, and peroxiredoxins, to produce H2O (Förstermann 2010). 
Under pathophysiological conditions when the ROS production is increased or prolonged, 
these enzymes are unable to cope with the ROS burden leading to pathological oxidative 
stress. 
Metabolic stress 
Metabolic stressors like hyperglycemia, hyperinsulinemia, and dyslipidemia may promote 
the formation of ROS and lead to ER stress and activation of UPR pathways. 
Hyperglycemia is a situation where the blood glucose levels are too high. It is a common 
feature in type 2 diabetes (T2D) where the proper body insulin function is disrupted even 
though the insulin levels may be elevated. This is known as hyperinsulinemia or insulin 
resistance. Dyslipidemia refers to abnormal lipid levels in the blood and may be triggered 
by hyperinsulinemia. Relatively common examples of dyslipidemia are both 
hypercholesterolemia and hypertriglyceridemia combined with reduced high-density 
lipoprotein (HDL) levels. 
Hyperinsulinemia has several mechanisms by which it can cause ER stress, and some of 






macrophages, resulting in ER stress and apoptosis. The mechanism is mediated by inhibition 
of sarcoplasmic/endoplasmic reticulum Ca2+ ATPase (SERCA) family and subsequent 
increase of cytosolic Ca2+ (Han et al. 2006, Liang et al. 2012). Compared to normal 
macrophages, insulin-resistant macrophages show increased ER stress and apoptosis 
following cholesterol loading. This is mediated via a transcription factor that increase the 
expression of a protein known as inhibitor of NF- B (I B). Nuclear factor B (NF- B) is a 
transcription factor and inhibition of NF- B activity by I B leads to decreased expression 
of various antiapoptotic and inflammatory genes under its control. This has been suggested 
to play a role in plaque development, necrotic core formation, and complications of 
atherosclerosis in diabetic individuals (Senokuchi et al. 2008). 
Insulin resistance may reduce ER stress responses in adipose tissue via inhibition of the 
metabolic phosphoinoside 3-kinase (PI3K) pathway of insulin signaling. This pathway is 
inhibited in insulin resistant T2D patients or by lipid infusion in normal individuals (Boden 
et al. 2014). In the study by Boden et al. (2014), hyperinsulinemia, caused by hyperglycemia 
in normal individuals increased the expression of ER stress markers in the adipose tissue. 
However, no change in ER stress markers was seen if the PI3K-pathway was inhibited by 
lipid infusion. Similarly, in T2D patients with suppressed PI3K-pathway, no increase in ER 
stress markers was observed following insulin administration. Thus, it was proposed that 
insulin induces ER stress via PI3K-mediated metabolic pathways, affecting glucose 
metabolism and protein synthesis (Boden et al. 2014). 
ER stress induced by obesity and inflammation has been suggested to promote hepatic 
insulin resistance that leads to increased gluconeogenesis and hyperglycemia, hallmarks of 
T2D (Kim et al. 2015). Insulin resistance in liver also causes an increase in lipogenesis that 
leads to elevated triglyceride-enriched very low-density lipoprotein (VLDL) secretion into 
circulation, which in turn promote development of atherosclerosis (Adiels et al. 2008). 
In the vasculature and cells of vascular origin, hyperglycemia, hyperinsulinemia, and 
hyperlipidemia upregulate inflammatory biomarkers (Perkins et al. 2015). Hyperglycemia 
also induces nitric oxide synthase dysfunction, peroxynitrite production, and LDL oxidation 
(Tanaka et al. 2009). Further, in VSMCs, hyperglycemia induces ROS production via 






rat model, hyperglycemia has in turn been shown to impair the regulation of intracellular 
Ca2+ sorting (Searls et al. 2010). 
Inflammation 
Inflammation and ER stress are closely linked. Several inflammatory factors may cause ER 
stress which further promotes the production of various pro-inflammatory molecules that 
attract inflammatory cells to the site of inflammation and thus amplify this positive feedback 
loop (Gargalovic et al. 2006, Zhang and Kaufman 2008). 
NF- B is a key regulator of the transcription of several inflammatory genes. It is activated 
during ER stress by phosphorylation of I B that normally keeps NF- B inactive (Pahl and 
Baeuerle 1995, Pahl and Baeuerle 1996, Jiang et al. 2003). Also, UPR-induced translational 
attenuation leads to increased NF- B activation. The half-life of I B is shorter than that of 
NF- B and thus I B is unable to suppress NF- B in a situation where the translation of new 
proteins is halted (Deng et al. 2004). Dissociation of I B from NF- B leads to exposure of 
its nuclear-localization signal and nuclear accumulation where it regulates the transcription 
of its target genes (Beg et al. 1992).  
Cytokines produced by inflammatory cells, such as TNF , may stimulate ER stress. TNF  
promotes intracellular ROS production thus leading to protein misfolding and ER stress 
(Xue et al. 2005). TNF , together with interleukin 1  and interferon , has also been shown 
to induce NO accumulation and subsequent nitrosative stress via pathways involving NF-
B activation, signal transducer and activator of transcription (STAT) signaling, and nitric 
oxide synthase upregulation (Kacheva et al. 2011). 
4. Renin-angiotensin system and angiotensin II type 1 receptor 
4.1 Renin-angiotensin system 
Blood pressure is regulated via a delicate signaling network comprising several organs and 
their hormonal products. Central in blood pressure regulation is the renin-angiotensin 






The main organs involved in the RAS are kidneys, liver, and lungs. When blood volume is 
too low, the juxtaglomerular cells in the kidneys secrete renin that activates the conversion 
of liver-derived angiotensinogen to Ang I. Ang I is further processed to octapeptide Ang II 
by lung-derived ACE that removes two C-terminal peptides from the decapeptide precursor 
Ang I. Ang II is a vasoconstricting peptide that increases blood pressure by constricting the 
blood vessels. In addition, it stimulates the release of aldosterone from the adrenal cortex 
that acts by increasing sodium and fluid reabsorption in the kidneys, thus further elevating 
blood pressure via an increase of blood volume (Figure 5). 
 
Figure 5. Renin-angiotensin system and blood pressure. 
There are two different receptors for angiotensin II: AT1R and angiotensin II type 2 receptor 
(AT2R). Of these, AT1R is the predominant receptor that accounts for the deleterious effects 
of angiotensin II, whereas AT2R usually has counteracting effects (Stoll et al. 1995, 






4.2. AT1R signaling in vascular renin-angiotensin system 
The Ang II-induced signaling via AT1R is mediated by activation of G-proteins coupled to 
the C-terminal tail of AT1R. These G-proteins can activate various signaling pathways that 
in the vasculature leads to vasoconstriction and transcription of various response genes 
(Figure 6). AT1R signaling leads to activation of a number of effector molecules, such as 
phospholipases and protein kinases (Touyz and Schiffrin 2000, Dinh et al. 2001). The acute 
response to angiotensin II in VSMCs includes activation of the phospholipase C (PLC) -
pathway that leads to formation of inositol 1,4,5-trisphosphate (IP3) and diacylglycerol 
(DAG) from phosphatidylinositol 4,5-bisphosphate. IP3 induces the release of Ca2+ from 
cellular compartments. DAG activates protein kinase C (PKC) that in turn activates the 
Na+/H+ exchanger affecting intracellular pH. Ang II further increases Na+ influx by 
activating the Na+-dependent Mg2+ exchanger. These events stimulate VSMC contraction 
by increasing myosin light chain phosphorylation and actin-myosin interaction. Myosin 
light chain is phosphorylated by myosin light chain kinase (MLCK). MLCK activation is 
primarily regulated by the IP3-route of PLC-pathway. IP3-mediated increase in intracellular 
Ca2+ leads to increased activation of calmodulin, a Ca2+-dependent activator of MLCK. 
This, in turn, leads to increased VSMC contraction via increased phosphorylation of myosin 







Figure 6. A schematic representation of some of the most important AT1R downstream signaling 
pathways in vascular cells. Adapted from Touyz and Schiffrin 2000. 
The long term effects mediated by AT1R signaling include activation of various signal 
transducers, including Janus kinase (JAK), signal transducer and activator of transcription 
(STAT), and mitogen-activated protein kinases (MAPK) and their signaling pathways. 
Activation of phospholipases A2 (PLA2) and D (PLD) by AT1R increase the release of 
arachidonic acid (AA) which can be further metabolized to vasocoreactive prostaglandins, 
for example by Cox-2 (Touyz and Schiffrin 2000, Dinh et al. 2001, Hu et al. 2002). AT1R 
may also have a central role in cellular redox signaling and in the adverse effects of oxidative 
stress. Several studies show increased production of ROS via activation of vascular NOXs 
following Ang II administration (Griendling et al. 1994, Rajagopalan et al. 1996, Lassègue 
et al. 2001, Gragasin et al. 2003). The mechanism is suggested to be mediated via AT1R in 
vascular cells where the specific blockade of AT1R function inhibits Ang II-induced NOX 






Besides G-proteins the cytoplasmic tail of AT1R associates with several other proteins such 
as Cox-2 (Sood et al. 2014) and angiotensin II receptor-associated protein (ATRAP) (Daviet 
et al. 1999). ATRAP is a negative regulator of Ang II-induced AT1R signaling by promoting 
AT1R internalization (Daviet et al. 1999, Cui et al. 2000, Lopez-Ilasaca et al. 2003). In 
VSMCs Ang II induces Cox-2 expression and the mechanism involves AT1R 
internalization (Ohnaka et al. 2000, Hu et al. 2002, Morinelli et al. 2008). In HEK293 cells, 
elements in the cytoplasmic tail of AT1R have been shown to directly associate with Cox-
2 and to downregulate its expression by ubiquitination and subsequent degradation (Sood et 
al. 2014). 
In addition to the classical RAS components there are a number of variations adding a layer 
of complexity to the system. Several truncated peptides of Ang I or Ang II have been 
discovered. These include Ang 1-7, Ang 1-9, Ang 2-8 (also known as Ang III) and Ang 3-
8 (also known as Ang IV). Ang 1-9 and Ang 1-7 are produced by angiotensin converting 
enzyme 2 (ACE2) -mediated removal of a single C-terminal peptide from Ang I or Ang II, 
respectively (Reudelhuber 2005, Fyhrquist and Saijonmaa 2008). The function of Ang 1-9 
is poorly known. Some evidence suggests that it might act via AT2R to reduce blood 
pressure and have a beneficial effect on heart, blood vessels, and kidneys against 
cardiovascular remodeling due to hypertension or heart failure (Ocaranza et al. 2014). Ang 
1-7 acts via binding to a receptor known as proto-oncogene mas (MAS1) and has been 
reported to act as a vasodilator and ACE inhibitor (Santos et al. 2003). Ang III is produced 
from Ang II by removal of an N-terminal peptide by aminopeptidase A and it can be further 
processed to produce Ang IV by aminopeptidase N. Ang III can bind to both AT1R and 
AT2R but with weaker affinity than Ang II (Reudelhuber 2005, Fyhrquist and Saijonmaa 
2008). The receptor for Ang IV was first characterized in 1992 (Swanson et al. 1992), but 
it took nearly a decade before it was identified as the insulin-regulated aminopeptidase 
(IRAP) (Albiston et al. 2001).  
In addition to the classical circulating RAS there is also a local tissue RAS that is found in 
several tissues and cell types. Among these, heart, vasculature, pancreas, brain, adipose 
tissue, and macrophages produce RAS components and are thus able to regulate RAS-
mediated functions outside the control of the circulating RAS (Bader and Ganten 2008, 






5. Regulation of AT1R expression 
AT1R was first cloned from rat (Murphy et al. 1991) and bovine (Sasaki et al. 1991), 
followed by cloning and characterization of the human AT1R complementary DNA 
(cDNA) (Furuta et al. 1992, Bergsma et al. 1992, Curnow et al. 1992). AT1R is a 41 kDa 
protein consisting of 359 amino acids. The gene encoding AT1R in humans is located in 
chromosome 3. It is a seven-transmembrane-spanning G-protein-coupled receptor with an 
extracellular N- and cytosolic C-terminus (de Gasparo et al. 2000). 
5.1. AT1R transcript variants 
The AT1R gene has been reported by NCBI to encode at least five different transcript 
variants (www.ncbi.nlm.nih.gov/gene/185). The variants consist of five alternative exons 
of which the last one contains the open reading frame for the functional protein whereas 
exons 1-4 are located in the 5’UTR. The five exons are of varying nucleotide length: exon 
1 is 257 nt; exon 2 is 84 nt; exon 3 is 58 nt; exon 4 is 157 nt; and exon 5 is 2015 nt. The four 
noncoding 5’ exons are present in various combinations together with the actual protein-
coding exon 5 (2015 nt). The currently-reported exon organizations between the different 
transcript variants are 1/2/5 (variant 1), 1/5 (variant 2), 1/3/5 (variant 3), 1/2/3/5 (variant 4), 
and 3/4/5 (variant 5) (Warnecke et al. 1999, Elton and Martin 2007, 
http://www.ncbi.nlm.nih.gov/gene/185). The transcript variant 2 consisting of exons 1 and 
5 encodes the predominant functional isoform. Exon 1 (257 nt) contains an IRES that 
functions in cap-independent translational activation during amino acid starvation-induced 
stress (Martin et al. 2003). Cellular stress is known to promote translation from uORFs and 
IRESs due to eIF2  phosphorylation (Vattem and Wek 2004, Holcik and Sonenberg 2005, 
Thakor and Holcik 2012). 
Inclusion of exon 2 (84 nt) to the transcript in variants 1 and 4 creates two alternative uORFs 
that leads to decreased expression of AT1R via reduced translation (Warnecke et al. 1999). 
Before encountering a stop codon, the first uORF is predicted to encode a 7 amino-acid-
long peptide and the second uORF, 11 and 9 amino acids in variants 1 and 4, respectively. 
It is thought that these uORFs are able to initiate translation, thus competing for ribosomes 






Inclusion of exon 3 (58 nt) in the transcript creates two additional in-frame uORFs that 
could lead to incorporation of an extra 32 or 35 amino acids to the N-terminus of the protein. 
The nucleotides surrounding the most upstream start codon are not optimal considering 
translation initiation whereas the downstream uORF is in suboptimal context. This results 
in translation of AT1R isoform harboring 32 additional N-terminal amino acids (Curnow et 
al. 1995, Martin et al. 2001). As demonstrated by Martin et al., transcripts containing exon 
3 are bicistronic, i.e. both the exon 3 and exon 5 start sites are used for translation and thus 
both the long and short receptor isoforms are produced from a single transcript (Martin et 
al. 2001). They further demonstrated that the binding of Ang II to the long isoform is weaker 
than to the predominant isoform and downstream signaling is activated at higher Ang II 
concentrations. This was hypothesized to allow fine-tuned regulation of Ang II responses 
by regulating the ratios of the two receptor isoforms. Moreover, as AT1R dimerizes with 
both AT1R and AT2R, creating homo and heterodimers, the long and short AT1R isoforms 
may add another level of regulatory complexity to the receptor function (AbdAlla et al. 
2000, AbdAlla et al. 2001a, AbdAlla et al. 2001b). 
The transcript variant harboring exon 3 and exon 4 (157 nt) is extremely rare and has been 
reported only from a human liver cDNA library (Guo et al. 1994). Taken together, these 
alternatively spliced isoforms enable a delegate fine-tuning, but at the same time increasing 
complexity, in the regulation of AT1R expression and function (Elton and Martin 2003, 
Elton and Martin 2007). 
5.2. Posttranscriptional regulation of AT1R 
AT1R expression is posttranscriptionally regulated by various physiological factors. 
Growth factors (Nickenig and Murphy 1994), Ang II (Nickenig and Murphy 1996), and 
estrogen (Wu et al. 2003) have been established as negative regulators of AT1R expression 
by a posttranscriptional mechanism. Thyroid hormones have been shown to decrease AT1R 
expression posttranscriptionally in VSMCs (Fukuyama et al. 2003) while increasing it in 
cardiomyocytes (Diniz et al. 2012). Other physiological factors that exert a positive impact 
on AT1R expression in posttranscriptional manner include LDL (Nickenig et al. 1997) and 






The mRNA of AT1R carries an approximately 900 nt long 3’UTR that contains several 
AREs (Pende et al. 1999). A number of proteins and miRNAs have already been identified 
to regulate AT1R expression via these elements in a posttranscriptional manner (for AREs, 
see Section 2.2).  
While the roles of these physiological factors, proteins, and miRNAs in AT1R regulation 
have been established, the exact detailed mechanisms of how they are interconnected remain 
poorly known. For the most part, the posttranscriptional regulators mediating the effects of 
the various physiological factors have not yet been identified. Similarly, the physiological 
factors regulating many of the identified trans-acting factors remain to be characterized (for 
cis-acting elements, see Section 2.1). 
5.2.1. AUF1 
AU-rich element RNA-binding protein 1, 37kDa (AUF1), also known as heterogeneous 
nuclear ribonucleoprotein D (HNRNPD), is best known for promoting the decay of ARE-
containing mRNAs (DeMaria and Brewer 1996, White et al. 2013). AUF1 was the first 
RNBP to be identified as a 3’UTR-dependent posttranscriptional regulator of AT1R 
expression. AUF1 acts as a negative regulator of AT1R expression by decreasing the half-
life of AT1R mRNA. Further, Ang II increases AUF1 expression, thus reinforcing its 
negative effect on AT1R (Pende et al. 1999). 
5.2.2. Calreticulin 
Calreticulin is another mediator of angiotensin II-induced destabilization of AT1R mRNA. 
Calreticulin is an ER-located protein classically described as a Ca2+-binding protein 
regulating intracellular Ca2+ homeostasis and its ER storage capacity. In addition to ER 
localization, calreticulin can be found in other cellular compartments where it has multiple 
functions (Michalak et al. 2009, Gold et al. 2010). Ang II induces phosphorylation of 
calreticulin that enables its binding to the 3’UTR of AT1R. Similar to AUF1, calreticulin 
also negatively regulates AT1R expression by promoting the decay of its mRNA (Nickenig 






have been performed in vascular smooth muscle cells of rat origin and thus the mechanisms 
have not yet been validated in humans. 
5.2.3. P100 
P100, also known as staphylococcal nuclease and tudor domain containing 1 (SND1), is a 
component of the RNA-induced silencing complex (RISC). It functions in several aspects 
of mRNA processing including spliceosome assembly as well as the coactivation of several 
transcription factors (Yang et al. 2002, Paukku et al. 2003, Caudy et al. 2003, Scadden et al. 
2005, Yang et al. 2007). P100 increases AT1R expression by 3’UTR-mediated stabilization 
and increased translation (Paukku et al. 2008). In addition to binding to AT1R 3’UTR under 
normal conditions, P100 also colocalizes with AT1R mRNA to SGs after heat shock or 
sodium arsenite treatment in HeLa cells (Gao et al. 2014). 
5.2.4. MicroRNAs 
In addition to RNBPs, certain miRNAs have been shown to target the 3’UTR of AT1R 
mRNA. TargetScan (http://www.targetscan.org/) predicts that AT1R mRNA may be a 
target for 302 miRNAs. The best characterized of the validated miRNAs is miR-155 that 
targets AT1R 3’UTR at a site containing a single nucleotide polymorphism (SNP) A1166C 
(rs5186). According to the Ensembl database (www.ensembl.org), the overall allele 
frequency for the minor allele is 0.118 but varies greatly between populations. The minor 
allele is most common among American (0.23) and European (0.27) populations whereas it 
is relatively rare in populations of African (0.02), East Asian (0.06), and South Asian (0.07) 
origin. The CC genotype of A1166C SNP is associated with increased aldosterone levels in 
hypertensive subjects and increased in vitro AT1R mRNA expression (Hannila-Handelberg 
et al. 2010). In large GWAS studies, however, no statistically significant association 
between AT1R SNPs and hypertension has been shown (Padmanabhan et al. 2015). The A 
allele-containing mRNA has been shown to be a target of miR-155-mediated 
downregulation, whereas the C allele leads to diminished interaction between the mRNA 
and miR-155 and thus increased AT1R expression (Zheng et al. 2010, Ceolotto et al. 2011, 
Haas et al. 2012). Further, miR-155 negatively affects Ang II-mediated VSMC viability and 






AT1R is expressed in the human gastrointestinal tract where it is involved in regulation of 
fluid and electrolyte transport, as well as contractions of the colonic smooth muscle cells. 
AT1R expression is posttranscriptionally regulated in the human colorectal adenocarcinoma 
cell line, C2BBe1, by miR-802. This miRNA is expressed mostly in fetal colon and in adult 
colon as well, yet to a considerably lesser degree (Sansom et al. 2010). 
Recently miR-410 has been shown to target the 3’UTR of AT1R mRNA in pancreatic 
cancer cells. The cancer tissue displays downregulation of miR-410 and upregulation of 
AT1R expression. The mechanism of miR-410 action is linked to suppression of cell 
growth, invasion, migration, and angiogenesis by suppressing AT1R expression (Guo et al. 
2015). 
6. AT1R pathophysiology 
6.1. Vascular AT1R in hypertension 
The vascular characteristics of chronic hypertension include vascular remodeling leading to 
stiffening and narrowing of the vessels due to increased media thickness (Intengan and 
Schiffrin 2001). Many hypertension-promoting cellular events are influenced by Ang II-
mediated signaling pathways (Kim and Iwao 2000, Schiffrin and Touyz 2004, Mehta and 
Griendling 2007). This emphasizes the role of AT1R in the adverse effects of hypertension 
and is supported by the beneficial effects of anti-hypertensive drugs targeted to counteract 
AT1R function (Oparil et al. 2001, PROGRESS Collaborative Group 2001, Gradman et al. 
2005).  
The acute vasoconstricting response of AT1R may partly be explained by the PLC pathway, 
as discussed earlier (chapter 4.2.). Other mechanisms may take part in the prolonged 
regulation. One of the major intracellular consequences of AT1R signaling is the production 
of ROS, in particular that of O2-, which are central contributors to AT1R-mediated pro-
hypertensive mechanisms. AT1R downstream signaling leads to activation of vascular 
NADPH oxidases, such as NOX1 on VSMCs or NOX4 on endothelial cells (Lassègue et al. 






Accumulation of O2- in turn leads to inactivation of NO by conversion to ONOO-, thus 
inhibiting the vasodilating effects of NO (de Gasparo 2002, Schulman et al. 2005). 
In vitro studies using rat VSMCs suggest that NO inhibits the adverse effects of Ang II by 
suppressing AT1R expression (Ichiki et al. 1998). Another study with rat VSMCs further 
shows that Ang II increases VSMC migration and O2- production, and together with insulin 
reduces NO availability (Yang et al. 2005). Thus, the Ang II-induced scavenging of NO by 
ROS may further increase AT1R upregulation via attenuating the AT1R suppressive 
functions of NO. Taken together, these studies support the role of AT1R as a pro-
hypertensive mediator. The central role of AT1R in regulation of blood pressure and 
development of hypertension is elegantly shown in animal models: mice expressing several 
copies of AT1R-gene or a constitutively active AT1R mutant develop hypertension, whereas 
AT1R knockout models show reduced blood pressure and response to Ang II (Ito et al. 1995, 
Le et al. 2003, Billet et al. 2007). 
6.2. AT1R in atherosclerosis 
There are several factors indicating a central role of AT1R in the progression of 
atherosclerosis, although the detailed mechanisms are poorly known. These include the role 
of AT1R in production of ROS, LDL oxidation and cellular uptake, production of pro-
inflammatory factors, and expression of adhesion molecules on vessel wall. Ang II-
mediated increase of ROS and decrease of NO leads to migration and infiltration of 
monocytes to the site of vascular endothelium under oxidative stress via increased 
expression of monocyte chemoattractant protein-1 (MCP-1) (Usui et al. 2000). Ang II-
mediated signaling of AT1R further promotes the adhesion of monocytes to the vascular 
wall by increasing the expression of adhesion molecule VCAM-1 in endothelial cells (Pueyo 
et al. 2000). 
Ang II and AT1R play a role also in the LDL-mediated adverse effects of atherogenesis. 
Normal and oxidized LDL upregulate AT1R expression in smooth muscle and endothelial 
cells of the vasculature, respectively (Nickenig et al. 1997, Li et al. 2000). Uptake of oxLDL 
by macrophages is further increased by AT1R-dependent upregulation of oxLDL receptor 






macrophages leads to formation of cholesterol-ester-enriched foam cells that are present 
already in the early stages of atherosclerotic lesions (Libby et al. 2011). OxLDL also 
increases NF- B expression and activation leading to increased transcription of pro-
inflammatory genes, such as interleukin 6 (IL-6) and TNF  (Li et al.2005). Inflammation 
also attenuates HDL facilitated cholesterol removal from macrophage foam cells (Gillespie 
et al. 2015). Furthermore, increased AT1R expression due to oxLDL is linked to NF- B 
activation (Li et al. 2000). 
Hypertension is a significant risk factor for the development of atherosclerosis, and certain 
drugs used to treat hypertension have beneficial effects against atherogenesis in 
experimental setups. In an animal study, the AT1R antagonist losartan showed a beneficial 
effect on atherogenesis in atherosclerotic rabbits on a high fat diet. Losartan decreased the 
levels of inflammatory factors IL-6 and C-reactive protein as well as reduced thickening of 
the tunica intima (Xu et al. 2013). Importantly, serum lipid and Ang II concentrations were 
similarly increased in both losartan treated and untreated rabbits on a high fat diet. This 
indicates that the losartan-mediated anti-atherosclerotic effect is not mediated by reduction 
of lipid or Ang II levels, but may include reduction of NF- B function, usually activated in 
response to Ang II. This limits the expression of NF- B-regulated inflammatory cytokines 
and adhesion molecules. Further, in a study by Ishii et al. (2013), AT1R blockers olmesartan 
and valsartan reduced the volume of coronary atherosclerotic plaques in human patients by 
ca. 5% after six months of treatment. The reduction in plaque volume was accompanied by 
reduction in blood pressure. Whether the beneficial effects of the drugs were due to reduced 
blood pressure or more specific actions involving AT1R suppression remained unclear. 
7. ER stress in atherosclerosis and hypertension 
There is a growing amount of evidence showing that ER stress and UPR are associated with 
the development of atherosclerosis and hypertension (Tabas 2010, Minamino et al. 2010, 
Zhou and Tabas 2013, Santos et al. 2014). This is rational considering that many of the 
known risk factors and cellular responses associated with atherosclerosis and hypertension 
are also known ER stressors. Indeed, several ER stress markers are expressed in 






of ER stress markers as well as apoptotic smooth muscle cells and macrophages, which has 
been hypothesized to play a role in plaque vulnerability (Myoishi et al. 2007, Sanson et al. 
2009). VSMCs apoptosis may promote plaque rupture as VSMCs produce collagen that 
normally stabilizes the fibrous cap (Geng and Libby 1995, Bauriedel et al. 1999). Another 
mechanism inducing plaque vulnerability involves the plaque resident inflammatory cells 
that secrete cytokines such as IL-6 that promote degradation of the extracellular matrix 
(Schieffer et al. 2000). Supporting this, in an atherosclerotic mouse model, VSMC apoptosis 
induced plaque vulnerability by reduced extracellular matrix, thinning of the fibrous cap, 
increased intimal inflammation, and accumulation of cell debris. VSMC apoptosis was 
linked to an increase of IL-6 levels and plaque MCP-1 expression (Clarke et al. 2006). In 
human VSMCs, OxLDL induces apoptosis by activating a pro-apoptotic signaling 
molecule, PKC isozyme  (PKC ). The mechanism is supposed to involve NOX-dependent 
production of ROS by oxLDL and activation of ER stress pathways. (Larroque-Cardoso et 
al. 2013). Though the detailed apoptosis-causing mechanisms in atherosclerosis are poorly 
understood, a chronic ER stress may be involved. Several ER stress-inducing agents have 
been described to induce VSMC and endothelial cell apoptosis in vitro (Scull and Tabas 
2011). The results remain, however, to be validated in vivo.  
ER stress also promotes inflammation associated with the progression of atherosclerosis. 
Free cholesterol accumulation in macrophages leads to ER stress and activation of pro-
inflammatory NF- B and MAPK pathways. This promotes inflammation by increased 
expression of inflammatory cytokines such as TNF  and IL-6 (Li et al. 2005). Oxidized 
phospholipids that accumulate in atherosclerotic lesions also trigger UPR and activate 
transcription factors needed for the expression of the various inflammatory cytokines 
(Gargalovic et al. 2006). 
The direct association of ER stress with hypertension has mostly been shown by studies 
using animal models. In mice with Ang II-induced hypertension, inhibition of ER stress has 
beneficial effects. Chemical chaperones, used as ER stress inhibitors, reduce blood pressure, 
expression of ER stress markers, endothelial dysfunction and cardiac damage (Kassan et al. 
2012). ER stress inhibitors also have beneficial effects on pulmonary artery hypertension in 
both rats and mice (Dromparis et al. 2013). Further, ER stress in the brain has been reported 






brain was shown to have a protective effect against both ER stress and hypertension (Young 
et al. 2012). The ER stress-induced hypertension by Ang II in the brain was later identified 







AIMS OF THE PRESENT STUDY 
This study was aimed at identifying novel AT1R 3’UTR-associated RNA-binding proteins 
(RNBP) and to explore their mechanistic role as posttranscriptional effectors of AT1R 
mRNA and protein expression. The specific aims were as follows: 
1. To identify novel AT1R 3’UTR-associated RNBPs involved in posttranscriptional 
regulation of AT1R expression (Studies I-III). 
2. To investigate the posttranscriptional mechanisms by which insulin increases AT1R 
mRNA and protein expression (Study II). 
3. To identify the physiological factors regulating the effects of the identified RNBPs 
on AT1R expression (Studies I and III). 
4. To map the binding sites of the identified RNBPs on AT1R 3’UTR (Studies I-III). 
5. To identify the posttranscriptional mechanisms, including regulation of mRNA 
stability, translation, and localization, by which the identified RNBPs mediate their 






MATERIALS AND METHODS 
Detailed descriptions of the materials and methods used in the different experiments can be 
found in the original publications I-III. 
1. Cell culture studies 
Cell culture 
HEK293 cell line, derived from human embryonic kidney cells, was chosen as the principal 
experimental model since it is an immortalized cell line of human origin. HEK293 cells do 
not express AT1R, or express only minimally, which could interfere with the experiments 
via competition. When possible, data on HEK293 cells were validated in primary cells, 
human VSMCs. These cells do express AT1R which enables investigation of the 
mechanisms in an endogenous environment. 
HEK293 cells were grown in Dulbecco’s modified Eagle’s medium supplemented with 10% 
fetal bovine serum (FBS), antibiotics, and glutamine. Early passage VSMCs were purchased 
from Lonza and grown in smooth muscle growth medium-2 with 5% FBS and supplements. 
To maintain the cell cultures, the sub-confluent cultures were detached from the culture 
plates with trypsin and split to new culture plates with appropriate seeding density. HEK293 
cells were split twice a week with a 1:10 seeding density, whereas VSMCs were split 
approximately once a week with a 1:5 seeding density. 
Transfections, transductions, and stimulations 
Transfections were used to manipulate the expression of specific proteins in HEK293 cells. 
To overexpress the protein of interest, an expression plasmid was transfected to the cells 
using Fugene 6 or Fugene 6 HD transfection reagent. In order to silence the expression of 
specific proteins, siRNAs against its mRNA were transfected to the cells by Lipofectamine 






In studies II and III, expression levels of endogenous HuR or TIA-1 were altered by 
lentiviral vector systems. The use of lentiviral vectors enables the creation of stable cell 
lines with either over or downregulated expression of the protein of interest. In study II, 
both HuR-overexpressing and HuR-silenced VSMC cell lines were created using pLenti6 
vector system (Sigma). In study III, TIA-1 expression was silenced in VSMCs by GIPZ 
lentiviral vector system (GE Healthcare). 
Both HEK293 and VSMC cells were subjected to various chemical treatments, including 
H2O2, insulin, thapsigargin, and angiotensin II in the experiments. 
2. Protein expression studies 
Cell fractionation and protein extraction 
The cells were lysed in appropriate lysing buffers or fractionated in cytoplasmic and nuclear 
extracts by a Cell Fractionation Kit (Pierce). The lysates were cleared by centrifugation and 
the protein concentrations were measured by Protein Assay kit (Bio Rad). 
RNA probe preparation 
In order to study binding and distribution of RNBPs on AT1R 3’UTR, either a full length 
or various fragments of the 3’UTR were synthesized in vitro. The RNA probes were 
prepared from cDNA templates by adding a T7 RNA polymerase promoter sequence to the 
5’-end of the polymerase chain reaction (PCR) products. An additional 30-nt-long poly-A 
tail was added to the probes used in affinity purification. The PCR products were separated 
by agarose gel electrophoresis and extracted from the gel. The RNA probes were 
subsequently transcribed from the template by MEGAscript in vitro transcription system 
according to the manufacturer’s instructions (Life Technologies). For probes to be used in 








Affinity purification was used to study protein-RNA interactions. In this method, the in vitro 
synthetizied AT1R 3’UTR RNA-probes, containing the poly-A tail, were coupled to poly-
T linked Oligotex beads. The RNA probes were incubated in cell lysates after which the 
beads were added to the mixture. After extensive washing, the samples consisting of RNA 
probes connected to the beads and the proteins associated to the probes were subjected to 
either mass spectrometric identification or to western blotting. 
Western blotting 
To study protein expression, equal amounts of cell lysates or samples from affinity 
purifications were boiled in reducing Laemmli buffer and separated by sodium dodecyl 
sulfate polyacrylamide gel electrophoresis (SDS-PAGE). The separated proteins were 
subsequently transferred to a nitrocellulose membrane by semi-dry western blotting. After 
the blotting, the membrane was blocked for nonspecific binding and then subjected to the 
primary antibodies against the protein of interest. The unbound antibodies were washed off 
and the primary antibodies were detected by either biotinylated or fluorescently-labeled 
secondary antibodies. After final washing, the fluorescently labeled secondary antibodies 
were visualized using Odyssey scanner (Li-Cor). The biotinylated antibodies were subjected 
to streptavidin horseradish peroxidase-conjugate and the emitted light was exposed to an X-
ray film. 
Mass spectrometry 
Proteins isolated by affinity purification were separated by SDS-PAGE and the gel was then 
subjected to silver (Study I and II) or Coomassie blue (Study III) staining to visualize the 
proteins. Protein bands of interest were cut out of the gel and digested in-gel to peptides 
with trypsin. The recovered peptides were subjected to matrix-assisted laser 
desorption/ionization-time of flight (MALDI-TOF) and MALDI-TOF/TOF using Ultraflex 
TOF/TOF instrument (Bruker) for mass analysis. The protein identification from the 
acquired data was performed using Mascot Peptide Mass Fingerprint and Mascot MS/MS 






Recombinant protein production and purification 
In study III a recombinant MBP-TIA-1 fusion protein was produced to study the direct and 
GAPDH-dependent association of TIA-1 to the 3’UTR of AT1R mRNA. The fusion protein 
was produced in E.coli using TIA-1 cDNA and a pMAL Protein Fusion and Purification 
System (New England BioLabs). 
Luciferase assay 
Luciferase expression constructs were used in order to study the effect of AT1R 3’UTR on 
protein expression under various conditions in Studies I-III. The constructs consisted of a 
coding sequence for luciferase protein and various fragments or the full length 3’UTR of 
AT1R mRNA fused downstream of the coding sequence. When transfected to HEK293 cells 
the mRNA transcribed by the construct was subjected to the regulatory mechanisms 
mediated by the 3’UTR fragment present in the transcript. The produced luciferase protein 
could be quantified from cell lysates by photometric methods, where the luminescent signal 
produced by the luciferase protein was measured with a luminometer. To establish the role 
of the 3’UTR on protein expression, the results were normalized against measurements 
obtained from cells transfected with a luciferase construct lacking the 3’UTR. 
Microscopy 
Immunofluorescent microscopy was used to study localization and colocalization of 
endogenous proteins in VSMCs by confocal microscopy. The cells were grown on glass 
coverslips and fixed using paraformaldehyde. The proteins of interest were detected with 
specific antibodies that were further stained with fluorescently-labeled secondary 
antibodies. After the coverslips were mounted on microscopy slides the cells were 
visualized by a laser-scanning confocal microscope. 
Immunofluorescent in situ hybridization was used to study the colocalization of endogenous 
AT1R mRNA and proteins. VSMCs were fixed on glass coverslips and hybridized with 
fluorescently-labeled RNA-probes against AT1R mRNA. After washing away the unbound 






protein of interest. The fluorescent labels were visualized with a conventional fluorescent 
microscope. 
Ligand-binding assay 
In studies I and III, a ligand-binding assay was used to determine AT1R expression on cell 
surface. Subconfluent VSMCs grown on 24-well culture plates were subjected to 
radiolabeled 125I-[Sar1,lle8] Ang II (PerkinElmer) or unlabeled Ang II as control to quantify 
the membrane expressed AT1R. Following incubation with the normal or radiolabeled Ang 
II, the cells were washed with PBS containing 0.1% BSA and lysed in 0.5 N NaOH. The 
AT1R expression was quantified by measuring the radioactivity of the bound radiolabeled 
Ang II using a liquid scintillator. The results were normalized against the samples incubated 
with unlabeled Ang II. 
In vitro translation 
The direct role of GAPDH on AT1R mRNA translation was studied in Study I by in vitro 
translation assay. Here, a luciferase construct with or without AT1R 3’UTR was in vitro 
translated and biotinylated in the presence or absence of purified recombinant GAPDH. The 
translated protein product was assayed by luciferase method and by detection of the biotin 
label in western blots. 
3. Protein-RNA interaction studies 
Protein-RNA co-immunoprecipitation 
Immunological methods were used to study protein-RNA interactions in Studies I-III. Cell 
lysates were prepeared using a lysis buffer that preserves the protein-RNA interactions 
(Peritz et al. 2006). The lysates were incubated with antibodies against the protein of 
interest. Protein G sepharose beads were added to the samples to bind the antibodies. After 
extensive washing, the proteins from the immunoprecipitated protein-RNA complexes were 
digested with proteinase K. The extracted RNA molecules were phenol-chloroform 






RNA electrophoretic mobility shift assay 
Changes in the protein-RNA interactions were explored in Studies I and II by RNA 
electrophoretic mobility shift assay (REMSA). Here, an in vitro synthesized and 
biotinylated RNA probe was added to cell lysates alone or together with an excess amount 
of unlabeled probe as competitor. Alternatively, an antibody against the protein of interest 
was added together with the biotinylated probe, in order to detect a specific protein-RNA 
complex by a band shift. Next the RNA, unbound to proteins, was digested with RNase, 
whereafter the samples were separated on a non-reducing SDS-PAGE and transferred to a 
nylon membrane. The biotin-labeled RNA was detected by chemiluminescence and 
observed for changes in the signal intensities or band shifts between different samples. 
Random mutagenesis 
In Study I, random mutagenesis was employed to detect the GAPDH-binding site at the 1-
100 region of the AT1R 3’UTR. A library of luciferase reporter constructs containing the 
1-100 3’UTR fragment with random mutations was created by GeneMorph II EZClone 
Domain Mutagenesis Kit (Agilent Technologies). From the created clones, those affecting 
protein expression were screened by luciferase assay. Binding of GAPDH to the mutated 
RNA was studied by affinity purification and REMSA. 
4. mRNA expression studies 
RNA isolation, cDNA synthesis and qPCR 
In Studies I-III, quantitative polymerase chain reaction (qPCR) was used to quantify mRNA 
abundance or half-life in VSMCs or HEK293 cells. After appropriate treatments, the cells 
were harvested and the total RNA isolated using Nucleospin RNA II kit (Macherey-Nagel). 
The total RNA or RNA from protein-RNA immunoprecipitation was reverse transcribed to 
cDNA by Superscript II or III First Strand Synthesis System (Invitrogen) using oligo(dT)12-
18 primers. The expression of the gene of interest and appropriate controls were quantified 








In Study I, the precipitated RNA from protein-RNA co-immunoprecipitation was subjected 
to expression profiling in order to identify mRNAs coupled to immunoprecipitated GAPDH. 
The RNA was converted to biotinylated complementary RNA, hybridized to GeneChips 







1. Effect of the 3’UTR on AT1R expression 
The regulatory effect of the AT1R 3’UTR on protein and mRNA expression was explored 
in Study I. HEK293 cells transfected with a luciferase construct containing the AT1R 
3’UTR downstream showed a significant decrease in protein expression when compared to 
controls lacking the 3’UTR. This indicates that the 3’UTR is a negative regulator. This was 
accompanied by a comparable, 3’UTR-dependent decrease in luciferase mRNA expressions 
levels. Similar 3’UTR-dependent change in mRNA expression was observed when the 
luciferase coding sequence was replaced with AT1R coding sequence, thus confirming that 
the 3’UTR is indeed the regulatory element (Figure 7). To further study the regulatory 
mechanisms by which the 3’UTR mediates its effect, both in vitro translation and luciferase 
mRNA half-life were measured in the presence and absence of the 3’UTR. Addition of the 
3’UTR to the mRNA was observed to both increase the mRNA degradation and to suppress 
its translation (Study I, Figures 1C and 1D). 
 
Figure 7. Effect of the AT1R 3’UTR on protein and mRNA expression. The results are shown as 






2. Binding and distribution of RNBPs to AT1R 3’UTR 
In studies I-III, three new RNBPs were identified to associate with the AT1R mRNA and 
regulate its expression via 3’UTR-mediated mechanisms. The identified proteins included 
GAPDH, HuR, and TIA-1. All of them are known RNBPs functioning in posttranscriptional 
regulation. The three proteins show distinct regulatory functions on AT1R expression. 
The RNBPs were identified by mass spectrometry after affinity purification of RNBPs from 
cell lysates using probes consisting of the AT1R 3’UTR. In Study I, a protein at around 36 
kDa range was observed to abundantly interact with various AT1R 3’UTR fragments and 
the protein was identified as GAPDH (Study I, Figure 2B). In Study II, the insulin-
mediated regulation of AT1R expression was explored. Another protein of around 36 kDa 
range was shown to exhibit increased association to the 3’UTR following insulin stimulation 
(Study II, Figure 2A). This protein was subsequently identified as HuR. In Study III, a 
protein of around 40 kDa was shown to specifically associate with full length AT1R 3’UTR 
and was identified as TIA-1 (Study III, Figure 1A). 
Using affinity purification with various AT1R 3’UTR fragments and western blotting, the 
binding of the proteins to the 3’UTR was confirmed and the binding sites mapped (Figure 
8). In Study I, GAPDH was shown to bind the proximal region, spanning the 100 first 
nucleotides of the 3’UTR. In Study II, HuR was identified to bind a region spanning 
nucleotides 300-887 and in Study III, TIA-1 binding sites were mapped to two distinct 
locations, the proximal 1-100 and distal 600-887 fragments of the 3’UTR (Figure 8). 
 
Figure 8. Binding and distribution of RNBPs to AT1R 3’UTR. Western blot images of GAPDH, 
HuR, and TIA-1 are displayed indicating binding to specific nucleotide regions. A combination of 






As observed by REMSA, the binding of GAPDH to the AT1R 3’UTR 1-100 region was 
direct as purified recombinant GAPDH did not require other proteins for the association 
(Figure 9A). Deletion of nucleotides 9 and 11 from the 3’UTR were able to abolish GAPDH 
binding, identifying this as the GAPDH responsive element. Computational modelling of 
the AT1R 3’UTR 1-100 region suggested a hairpin-like structure that is disrupted by the 
9/11 deletion (Figure 9B). When analyzing the sequences from several GAPDH target 
mRNAs, the GAPDH motif was identified as an AU-rich sequence element (Figure 9C). 
 
Figure 9. GAPDH-binding motif of AT1R 3’UTR. (A) REMSA showing the binding of purified 
GAPDH to AT1R 3’UTR 1-100 region. (B) REMSA showing the inhibition of GAPDH binding to 
AT1R 3’UTR 1-100 by 9/11 deletion. The predicted structure of the wild type and deletion RNAs 
is shown. The deleted nucleotides are shown in red (1-100). (C) The consensus GAPDH target 






Insulin-induced association of HuR with AT1R mRNA was confirmed by 
immunoprecipitation coupled to qPCR from VSMCs (Study II). HuR was 
immunoprecipitated with a HuR-specific antibody from VSMCs before or after insulin 
stimulation and the associated AT1R mRNA was quantified by qPCR. At baseline, AT1R 
mRNA showed increased association to HuR when compared to a control where nonspecific 
IgG was used for immunoprecipitation. After insulin stimulation, AT1R mRNA association 
to HuR further increased when compared to the IgG control. No significant change in AT1R 
mRNA association was observed to other known AT1R 3’UTR-binding proteins in response 
to insulin stimulation (Study II, Figure 2B). 
Since GAPDH was identified to associate to the proximal 3’UTR region (Study I), the 
possible interaction between TIA-1 and GAPDH at this site was explored in Study III. TIA-
1 binding to AT1R 3’UTR was shown to be GAPDH-dependent, as GAPDH silencing 
attenuated TIA-1 binding to the 1-100 region as observed by affinity purification, whereas 
TIA-1 silencing had no effect on GAPDH binding (Study III, Figure 3A). Further, using 
purified GAPDH and TIA-1-MBP fusion protein in affinity purification, TIA-1 binding to 
the 1-100 region was increased by addition of GAPDH to the samples. GAPDH binding 
however, was not significantly dependent on the presence of TIA-1 (Study III, Figure 3B). 
These data suggest that GAPDH binds to the AT1R 3’UTR directly, whereas TIA-1 requires 
GAPDH for the association at the proximal site. Using purified proteins in the affinity 
purification also demonstrated that TIA-1 and GAPDH do not require any other proteins for 
the association with the 3’UTR. TIA-1 binding to the distal 600-887 region was direct as 
GAPDH did not bind to this region in affinity purification from cell lysates nor was TIA-1 
binding affected by GAPDH in affinity purification using purified proteins (Study III, 
Figures 3A and 3B). To study endogenous protein-RNA interactions, fluorescent in situ 
hybridization against AT1R mRNA combined with immunofluorescent staining was used. 
In this experimental setup both TIA-1 and GAPDH were shown to colocalize with AT1R 






3. RNBP effects on AT1R expression 
The mechanism by which GAPDH regulates AT1R expression was investigated in Study I, 
using a luciferase reporter gene expression system. GAPDH was identified as a negative 
regulator of AT1R expression via a 3’UTR-mediated mechanism. Following GAPDH 
silencing, a luciferase reporter gene exhibited an AT1R 3’UTR-dependent increase in 
luciferase protein expression in HEK293 cells, whereas the luciferase mRNA was reduced. 
Similar responses were seen in expression of both endogenous AT1R protein and mRNA in 
VSMCs (Figure 10). This suggests that GAPDH stabilizes AT1R mRNA while suppressing 
its translation. As nucleotides 9 and 11 of the 3’UTR are needed for GAPDH binding, a 
luciferase construct lacking these nucleotides showed no significant response to GAPDH 







Figure 10. RNBP effects on AT1R expression. AT1R 3’UTR-binding RNBPs have been silenced 
as indicated. Luciferase protein and mRNA expression was studied in HEK293 transfected with an 
AT1R 3’UTR-bearing luciferase construct. Endogenous AT1R protein and mRNA levels were 
measured in VSMCs. The results are shown as mean ± SD of relative quantities. A combination of 
data from Studies I- III. 
In Study II, the mechanisms underlying HuR-mediated AT1R regulation were explored. 
Silencing of HuR expression in HEK293 cells expressing a luciferase-reporter-gene 
construct decreased the luciferase expression in an AT1R 3’UTR-dependent manner. 
Similarly, HuR silencing reduced the endogenous AT1R mRNA in VSMCs (Figure 10). In 
line with this, HuR overexpression had a positive effect on both protein and mRNA levels 






affecting the mRNA expression. The mechanism was identified to be mediated via HuR-
induced stabilization of the mRNA as HuR overexpression increased the half-life of a 
luciferase mRNA containing the AT1R 3’UTR, whereas silencing of HuR expression had 
an opposite effect (Study II, Figure 5). 
The regulatory mechanisms of TIA-1-mediated AT1R expression were investigated in 
Study III. TIA-1 silencing increased the protein expression of an AT1R 3’UTR-containing 
luciferase reporter construct in HEK293 cells and the endogenous AT1R protein expression 
in VSMCs. Conversely, endogenous AT1R mRNA levels were reduced in VSMCs 
following TIA-1 silencing (Figure 10). Collectively, these results indicate that under 
normal conditions TIA-1 suppresses protein expression while stabilizing the mRNA. 
Further, both identified TIA-1 binding sites were independently capable of mediating the 
TIA-1 effect (Study III, Figures 2B and 2C). However, as TIA-1 binding to the proximal 
region required GAPDH, inhibition of GAPDH binding, by using 3’UTR constructs lacking 
nucleotides 9 and 11, attenuated the TIA-1 effect at the proximal site (Study III, Figure 
3C). Neither TIA-1 nor GAPDH overexpression had any significant influence on the 
luciferase expression levels when GAPDH binding was blocked by this deletion construct. 
4. Physiological and pathophysiological AT1R regulators and 
their RNBP mediators 
The 3’UTR of AT1R mRNA destabilizes the mRNA under normal conditions as shown in 
Study I. Incorporation of the 3’UTR in a reporter gene construct leads to both decreased 
protein and mRNA expression. In studies I-III various environmental stimulations were 
shown to regulate the 3’UTR-mediated effects via the identified three RNBPs: GAPDH, 
HuR, and TIA-1. 
In study I the effect of GAPDH on AT1R regulation was shown to be regulated by H2O2. 
Exposure of VSMCs to various concentrations of H2O2 increased AT1R expression in a 
dose-dependent manner, as shown by a western blot (Study I, Figure 6A). The increase in 
AT1R expression was coupled to both decreased GAPDH expression and reduced 
association of GAPDH to AT1R 3’UTR (Study I, Figures 6A and 6B). The diminished 






GAPDH expression, as treatment of VSMC lysates with H2O2 decreased the association 
without affecting GAPDH levels (Study I, figure 6C).  
The effect of GAPDH on H2O2-mediated regulation of AT1R was further studied by 
luciferase assay in HEK293 cells transfected with a control or AT1R 3’UTR containing 
luciferase reporter construct, together with a control or GAPDH expression vector. 
Subsequent exposure of the cells to H2O2 increased the luciferase expression when the 
AT1R 3’UTR was present. Simultaneous overexpression of GAPDH diminished the H2O2 
effect validating the role of GAPDH as a mediator of the H2O2 response (Figure 11). This 
was further confirmed by the observation that a luciferase construct lacking the nucleotides 
9 and 11, needed for GAPDH binding, was unresponsive to both GAPDH overexpression 







Figure 11. Factors regulating the effects of the identified GAPDH, HuR, and TIA-1 on AT1R 
expression. For H2O2 and insulin experiments, HEK293 cells were transfected with a luciferase 
expression construct bearing AT1R 3’UTR and the luciferase activity was measured to determine 
protein expression. In the thapsigargin experiment, the endogenous AT1R expression in VSMCs 
was measured by ligand-binding assay. The proteins of interest were overexpressed or silenced as 






In Study II, insulin stimulation of VSMCs was shown to increase endogenous AT1R protein 
expression (Study II, Figure 1A). In line with this, insulin increased AT1R mRNA 
expression in a dose-dependent manner by increasing the mRNA half-life (Study II, 
Figures 1B and 1C). Insulin stimulation of HEK293 cells transfected with a luciferase 
reporter construct further demonstrated that the time-dependent increase in AT1R 3’UTR-
mediated luciferase expression was coupled to increased nucleocytoplasmic HuR 
translocation and association with AT1R 3’UTR, as observed by affinity purification and 
REMSA (Study II, Figures 3A-C).  
The effect of insulin on AT1R regulation was shown to be mediated by HuR. HEK293 cells 
transfected with a luciferase reporter construct exhibited an AT1R 3’UTR-dependent 
increase in luciferase expression following insulin stimulation. Co-transfection with a HuR 
expression construct showed an increase in luciferase expression similar to that upon insulin 
stimulation, but no additional insulin effect was observed. Silencing HuR expression in turn 
decreased the luciferase expression and rendered it unresponsive to insulin (Figure 11). In 
line with these results, a similar effect on endogenous AT1R protein and mRNA expression 
was observed in VSMCs where HuR was either overexpressed or silenced by lentiviral 
expression constructs prior to insulin stimulation (Study II, Figure 4C). This shows that 
HuR is mediating the insulin effect on AT1R regulation. 
Using luciferase constructs containing various AT1R 3’UTR fragments the insulin 
responsive element was identified to require at least the 637 first nucleotides of the 3’UTR. 
The first 607 nucleotides had only a minor effect on the reporter gene expression. This 
placed the insulin responsive element between nucleotides 607-637 (Study 2, Figure 6B). 
Using the same luciferase constructs together with HuR overexpression, the HuR responsive 
element was shown to be the same as noted for insulin (Study II, Figure 6C). This further 
supports the assumption that HuR serves as the mediator of the insulin response on AT1R 
expression, 
As the function of HuR on posttranscriptional regulation of its targets requires its 
nucleocytoplasmic translocation (Fan and Steitz 1998a, Doller et al. 2008), the effect of 
blocking HuR translocation process on AT1R expression was studied. Silencing of HuR 






HEK293 cells, transfected with luciferase reporter gene construct, resulted in decreased 
responsiveness to insulin in a 3’UTR-dependent manner (Study II, Figures 7A and 7B). 
As shown by western blotting, the effect was accompanied by inhibition of insulin-induced 
nucleocytoplasmic HuR translocation. In line with this, as studied by immunofluorescent 
microscopy, insulin stimulation increased cytoplasmic HuR accumulation in VSMCs 
whereas LMB inhibited the insulin-induced nuclear export of HuR (Study II, Figure 7C). 
In study III, the TIA-1-mediated effects on AT1R were observed to be regulated by ER 
stress. Ligand-binding experiments revealed that thapsigargin-induced ER stress increased 
the AT1R protein expression in VSMCs. Silencing TIA-1 expression by lentiviral shRNA 
constructs led to increased baseline AT1R expression but no additional effect was seen after 
thapsigargin exposure. (Figure 11). Thapsigargin treatment induced the expression of 
various stress marker proteins and reduced the total mRNA expression levels while the 
relative AT1R mRNA expression was increased (Figure 12). Endogenous mRNA levels 
also showed no significant response to thapsigargin in TIA-1-silenced VSMCs compared to 
controls. In unstimulated cells however, TIA-1 silencing decreased the relative baseline 
AT1R mRNA levels, in line with previous results (Study III, Figure 5B). This indicates 
that TIA-1 suppresses AT1R expression under normal conditions and that the suppression 







Figure 12. Thapsigargin effect on AT1R mRNA expression. (A) Thapsigargin-induced increase in 
stress marker proteins and relative AT1R mRNA expression. A combination of data from Study 
III. (B) Thapsigargin effect on total mRNA levels of AT1R and actin that was used for the 
normalization of the results (unpublished data). The results are shown as mean ± SD of relative 
quantity to results at 0 hours. 
Using immunofluorescent microscopy and fluorescent in situ hybridization, both TIA-1 and 
GAPDH were shown to colocalize with AT1R mRNA in VSMCs under normal conditions. 
However, thapsigargin-induced ER stress dissociated TIA-1 from AT1R mRNA. During 
ER stress, TIA-1 translocated to SGs, leaving AT1R mRNA to the cytoplasm. Association 
of GAPDH to AT1R mRNA was unaffected by ER stress while a fraction of GAPDH 







Figure 13. Effect of ER stress on TIA-1 or GAPDH cellular localization and association to AT1R 
mRNA. (A) Localization of TIA-1, GAPDH, and a SG-marker protein PABP in unstressed 
VSMCs (A-C) or in VSMCs under ER stress (D-F). (B) Association of TIA-1, GAPDH, or PABP 
to AT1R mRNA in unstressed VSMCs (A-C) or in VSMCs under ER stress (D-F). The arrows 






The results from Studies I-III with respect to the identified AT1R 3’UTR trans-acting 
factors, their various effects and modes of action are summarized in Table 3. 
Table 3. Summary of the AT1R 3’UTR trans-acting factors and their regulatory mechanisms. ND 
= not determined. 
ARE-BP Effect Mechanism Experimental model Region (3’UTR) 
Binding  
to mRNA Study 
GAPDH Negative Translation & stability 
H2O2 dissociates 
GAPDH from 3’UTR 1-100 Direct I 
HuR Positive Stability Insulin increases HuR association to 3’UTR 607-637 ND II 
TIA-1 Negative Translation & stability 
Thapsigargin dissociates 
TIA-1 from 3’UTR 
1-100 
600-887 
Via GAPDH (1-100) 







1. AT1R 3’UTR trans-acting factors 
1.1 Initial studies 
The present series of investigations were set up to identify novel AT1R 3’UTR trans-acting 
factors involved in the regulation of AT1R expression. The first indications of 3’UTR-
mediated regulation of AT1R mRNA were made by Bonnardeaux et al. (1994) when they 
characterized a 3’UTR-located A1166C SNP that seemed to be associated with essential 
hypertension. Their study suggested that the identified SNP might function as a marker for 
an unidentified functional variant. Later this SNP was shown to overlap with a miR-155 
binding site. The CC genotype was further shown to inhibit miR-155 binding and to be 
associated with both elevated blood pressure and AT1R protein expression (Ceolotto et al. 
2011). Since the first discovery of the A1166C SNP, several other studies focusing on the 
regulation of AT1R expression on mRNA level suggested a posttranscriptional model 
orchestrated by RNBPs (Lassègue et al. 1995, Nickenig and Murphy 1996). Finally AUF-1 
was identified as such a posttranscriptional regulator (Pende et al. 1999). Since then, several 
other proteins and miRNAs have also been identified, implicating the 3’UTR as one of the 
key regulatory targets of AT1R expression (Nickenig et al. 2002, Paukku et al. 2008, 
Sansom et al. 2010, Guo et al. 2015). In this thesis, three new RNBPs have been 
characterized as 3’UTR-mediated posttranscriptional regulators of AT1R expression. The 








Figure 14. A schematic representation of known AT1R 3’UTR trans-acting factors and their 
binding sites. Locations of AREs are shown (arrows). *, the binding site is based on experiments 
performed in the rat and no details are available in humans. 
1.2 GAPDH 
GAPDH was shown to associate with the 3’UTR of AT1R mRNA, increasing the mRNA 
stability while suppressing its translation under normal conditions (Study I). When exposed 
to an oxidizing environment, however, GAPDH was released from the mRNA leading to 
increased AT1R protein expression. The dissociation of GAPDH from AT1R mRNA in 
response to H2O2 treatment, was coupled with overall reduction of GAPDH expression. 
Rodriguez-Pascual et al. (2008) and Kondo et al. (2011) identified GAPDH as a redox-
sensitive regulator of mRNA expression. A similar mechanism has been proposed in the 
present study where H2O2 abolishes GAPDH-AT1R 3’UTR interaction. H2O2 is known to 
reduce both GAPDH half-life (Sukhanov et al. 2006) and activity (Janero et al. 1994, 
Schuppe-Koistinen et al. 1994, Ciolino and Levine 1997). This is in line with the present 
study showing that H2O2 induces reduction of both GAPDH expression and its association 
to AT1R 3’UTR. It should be noted that H2O2 increases both eNOS expression and 
enzymatic activity, thus increasing NO production (Drummond et al. 2000, Thomas et al. 
2002). In addition to H2O2, NO is a known inhibitor of GAPDH by nitrosylation of its active 
site (McDonald and Moss 1993, Padgett and Whorton 1995). Other oxidation-induced 
modifications such as aggregation of GAPDH (Nakajima et al. 2007) or protein-protein 
interactions (Kim et al. 2003) induced by H2O2, should also be considered as possible 







While the function of GAPDH in SG assembly has not been described in detail, the present 
study demonstrates partial localization of GAPDH to SGs after thapsigargin-induced ER 
stress (Study III). This is supported by another study where GAPDH was identified as an 
SG component when searching for SG components after arsenite-induced SG assembly 
(Ohn et al. 2008). In that study, the role of GAPDH in SGs was not described in more detail, 
however. The present thesis further supports the localization of GAPDH to SGs but its exact 
physiological role in these organelles remains to be further explored. 
1.3 HuR 
In the present study HuR was shown to mediate the insulin-induced upregulation of AT1R 
protein expression via a posttranscriptional mechanism. HuR associates with the AT1R 
3’UTR leading to increased mRNA stability, the effect of which is increased by insulin 
(Study II). 
The relationship between insulin and AT1R has been established previously. In a study by 
Nickenig et al. (1998), insulin increased AT1R expression in rat VSMCs, and the underlying 
mechanism was reported to involve posttranscriptional stabilization of the AT1R mRNA. 
In the present study, the insulin responsive element in human AT1R mRNA was mapped to 
the 3’UTR. A luciferase reporter construct containing the AT1R 3’UTR showed increased 
mRNA and protein expression in response to insulin stimulation. 
When searching for proteins mediating the insulin effect via the AT1R 3’UTR, HuR was 
identified as a candidate. HuR is one of the best characterized ARE-BPs. As such, it was 
not unexpected to find it associated with the AT1R 3’UTR bearing multiple AREs (Study 
II). In fact, Pende et al. (2008) were the first to suggest a possible role of HuR in 
posttranscriptional regulation of AT1R. They demonstrated that Ang II induced the 
nucleocytoplasmic translocation of a HuR fusion protein, and a purified HuR fusion protein 
was shown to bind AT1R 3’UTR. The mechanisms or effects of HuR on AT1R expression 
were not studied in more detail by Pende et al. (2008). The present study further expands 
these original observations. In fact, it was confirmed that endogenous HuR was able to bind 
to the AT1R 3’UTR leading to increased stability of the mRNA (Study II). This is in line 






One of the prerequisites for HuR action is its nucleocytoplasmic translocation. This is 
consistent with the results from the present study in which insulin induced this translocation. 
A transporter protein CRM-1 was shown to mediate HuR translocation and to be required 
for the insulin-induced upregulation of a luciferase reporter construct bearing AT1R 3’UTR. 
Inhibition of CRM1 by siRNA, or by a specific blocker (LMB), inhibited the cytoplasmic 
HuR translocation and attenuated the insulin effect on luciferase expression. This suggests 
that the insulin-induced upregulation of AT1R expression by HuR require the 
nucleocytoplasmic translocation of HuR by CRM1. 
In the study by Nickenig et al. (1998), insulin-mediated upregulation of AT1R expression 
was identified as MAPK-dependent. Another study by Subbaramaiah et al. (2003) reported 
that stabilization of Cox-2 mRNA by HuR was dependent on p38 MAPK and MAPK-
activated protein kinase 2 (MK2). Insulin is known to both activate p38 MAPK and induce 
the nucleocytoplasmic translocation of CRM1 (Begum and Ragolia 2000, Somwar et al. 
2000, Kim et al. 2011). In addition, a study by Gurgis et al. (2015) reported that increased 
IL-6 mRNA stability was dependent on the p38 MAPK-MK2-HuR pathway. Taken 
together, these previous observations combined with the results from Study II, describing 
insulin-induced nucleocytoplasmic translocation of HuR by CRM-1, paint a broad outline 
of a possible signaling cascade required for the insulin-induced stabilization of AT1R 
mRNA by HuR (Figure 15). However, this signaling cascade and its detailed mechanisms 







Figure 15. Outline of a possible signaling cascade resulting in insulin-induced association of HuR 
with AT1R mRNA 
1.4 TIA-1 
TIA-1 was shown to bind to both the proximal and distal regions of the AT1R 3’UTR (Study 
III). The association at the proximal site was identified to be GAPDH-dependent but binding 
at the distal site was direct and independent of other proteins. Three different mechanisms 
for interaction may be proposed (Figure 16). In model A the two TIA-1 binding sites are 
independent and do not interact with each other, whereas in model B homodimerization of 
TIA-1 from the two sites is proposed to cause a loop-structure in the mRNA. The 
homodimerization of TIA-1 is supported by a study describing TIA-1 aggregation via its 
prion-related domain in SG assembly (Gilks et al. 2004). Looping of the mRNA would 
enable protein-protein or protein-RNA interactions over distinct regions. The H2O2-induced 






proximal site suggesting that this site might be involved in the ROS sensitive regulation via 
TIA-1 and GAPDH. In model B, GAPDH and TIA-1 dissociation from the proximal site 
would further attenuate the conformational change of the mRNA molecule by disrupting the 
loop structure. TIA-1 binding at the distal site is not GAPDH-dependent and the TIA-1 
effects at this site may be controlled by some other mechanisms.  
 
Figure 16. Proposal of models for GAPDH-TIA-1 interactions with AT1R 3’UTR 
In model C, TIA-1 would only bind to the distal region and the proximal association (Study 
III) would be due to protein-protein interactions of TIA-1 and GAPDH over the distinct 
binding sites. This is supported by a previous study showing protein-protein interactions 
between TIA-1 and a small nuclear ribonucleoprotein (snRNP) in spliceosome assembly 
(Förch et al. 2002). Also in model C, GAPDH and TIA-1 heterodimerization would cause 
a loop structure in the mRNA. Dissociation of either of the proteins would lead to disruption 






The best described role of TIA-1-induced translational suppression involves the recruitment 
of target mRNAs to SGs during cellular stress. However, AT1R mRNA was shown to be 
suppressed by TIA-1 under normal conditions but escape recruitment to SGs by dissociation 
of TIA-1 (Study III). The mechanism of TIA-1-mediated regulation of its target mRNAs in 
unstressed environment is poorly known but it may involve regulation of transcript variants 
via splicing or translational suppression and mRNA decay (Izquierdo and Valcárcel 2007, 
Yamasaki et al. 2007). Further, the 3’UTR is known to be involved in translational 
regulation of some mRNAs. While the detailed mechanisms are still poorly known, they 
involve protein-protein interactions over the 5’ and 3’UTRs by looping of the mRNA and 
affecting the assembly of the translation initiation complexes (Szostak and Gebauer 2013). 
The TIA-1-mediated conformational changes in AT1R mRNA via protein-protein 
interactions, proposed in Figure 16 models B and C, would support this mechanism but this 
remains to be confirmed. 
2. AT1R as a stress-regulated receptor 
The expression of AT1R has been shown to be increased under various conditions 
associated with both the development of CVDs and cellular stress. In this thesis, three 
models of such stressful environments and their affected RNBPs were explored: oxidative 
stress via GAPDH (Study I), hyperinsulinemia via HuR (Study II), and ER stress via TIA-
1 (Study III). 
2.1. AT1R and cellular stress 
H2O2 increases the ROS load in the cells, exposing them to oxidative stress. The association 
between ROS and AT1R expression is well known. While AT1R activation increases ROS 
production, AT1R expression and function have been shown to be increased by ROS (Li et 
al. 2000, Nickenig and Harrison 2002, Sungkaworn et al. 2013, Bhatt et al. 2014). This may 
lead to a vicious cycle accelerating the cellular oxidative stress. However, the molecular 
mechanisms involved in ROS-dependent upregulation of AT1R expression are poorly 
known. In Study I, H2O2 increased AT1R protein expression by releasing the translational 






upregulation by H2O2 to involve activation of transcription factor NF- B. Interestingly, NF-
B activation is also induced by AT1R activation (Kranzhöfer et al. 1999, Mitra et al. 2010, 
Young et al. 2015). This would enable a positive feedback loop promoting AT1R 
upregulation. Taken together, these results shed light on how AT1R expression may be 
upregulated by ROS via both transcriptional and posttranscriptional mechanisms. 
In Study II, the effect of insulin on posttranscriptional regulation of AT1R expression was 
explored. Type 2 diabetes (T2D) is a common risk factor for CVD and is often associated 
with hyperinsulinemia. Previous studies have established the link between T2D, insulin, and 
AT1R expression. In atherosclerotic arteries of a diabetic mouse model, AT1R expression 
is increased compared to non-diabetic arteries (Ihara et al. 2007). Further, in human carotid 
artery samples from T2D patients, AT1R expression is increased compared to non-diabetic 
patients. In VSMC cultures from these samples, similar baseline increase in AT1R 
expression and insulin-induced increase in both AT1R mRNA and protein levels may be 
observed (Hodroj et al. 2007). In the study by Nickenig et al. (1998), insulin was shown to 
increase the relative AT1R mRNA levels in both a time and dose-dependent manner and the 
results were coupled to increased expression of the membrane-bound receptor. While 
insulin had no effect on the transcription rate of AT1R gene, it increased the half-life of the 
mRNA. Thus, a posttranscriptional regulatory mechanism was proposed (Nickenig et al. 
1998). This is in accordance with the results of the present study in which the positive insulin 
effect on AT1R expression was mediated via the 3’UTR of AT1R mRNA (Study II). Insulin 
increased cytoplasmic HuR accumulation and binding to AT1R 3’UTR. Insulin-mediated 
binding of HuR to AT1R 3’UTR was further shown to stabilize the mRNA and increase 
protein expression. While the functionality of this posttranscriptional regulatory mechanism 
remains to be confirmed in vivo, it proposes an elegant model of how AT1R expression may 
be regulated by insulin. 
The fact that both ROS and insulin increase AT1R expression, and that both are known ER 
stressors, raises the question of whether AT1R is a general ER-stress-regulated protein. 
Thapsigargin induces ER stress by increasing the cytoplasmic free Ca2+ levels via inhibition 
of the SERCA family of Ca2+ pumps (Thastrup et al. 1990, Lytton et al. 1991). In this thesis, 
the effect of ER stress on AT1R expression was explored using thapsigargin. AT1R mRNA 






to be confirmed, this would allow AT1R mRNA to remain accessible for the translational 
machinery during ER stress. This is supported by the relative increase in both AT1R mRNA 
and protein levels during ER stress in VSMCs. This is in line with a previous study 
describing that AT1R mRNA remains translationally active under cellular stress (Martin et 
al. 2003). In addition to posttranscriptional mechanisms, AT1R expression may be 
upregulated under cellular stress via NF- B-mediated transcriptional control. A number of 
studies show that NF- B is activated by oxidative and ER stress (Pahl and Baeuerle 1995, 
Pahl and Baeuerle 1996, Deng et al. 2004). This suggests that both transcriptional and 
posttranscriptional mechanisms regulate AT1R expression during cellular stress. 
While ER stress may be caused by several mechanisms it is not known if they all have 
similar impact on AT1R expression. H2O2-induced oxidative stress was shown to dissociate 
GAPDH from AT1R mRNA (Study I) while during thapsigargin-induced ER stress TIA-1 
was dissociated but GAPDH remained colocalized with AT1R mRNA (Study III). At the 
same time, a fraction of GAPDH localized to SGs. This suggests that a different pool of 
GAPDH localizes to SGs than that associating with AT1R mRNA. Whether this is due to 
some posttranslational modification of GAPDH remains to be answered. Different cellular 
stressors may also have different effects on the mRNA-binding capabilities of GAPDH. 
Phosphorylation of eIF2  is considered to be a proxy for ER stress and a prerequisite to SG 
formation. However, various stressors phosphorylate eIF2  via different kinases (Donnelly 
et al. 2013). In addition, the mRNA subsets affected by phosphorylation of eIF2  have been 
shown to differ depending on the kinase phosphorylating eIF2  (Dang Do et al. 2009). 
Emara et al. (2012) proposed that H2O2-induced SGs differ from the canonical SGs and are 
assembled independently of eIF2  phosphorylation. Further, Larroque-Cardoso et al. (2013) 
showed that in human VSMCs, oxLDL is capable of inducing eIF2  phosphorylation but 
require PKC  for activation of pro-apoptotic pathways, whereas thapsigargin is not 
dependent on PKC  and can also activate the apoptotic pathway in PKC  deficient cells. 
Taken together, the ER stress pathways are diverse and complex, suggesting that the stress-
induced regulation of AT1R expression may differ depending on the stressor. 
The cellular stressors used in this thesis and the mechanism by which they increase AT1R 







Figure 17. A summary of the mechanisms by which oxidative stress, hyperinsulinemia, and ER 
stress increase AT1R expression by affecting GAPDH, HuR, and TIA-1 binding to the 3’UTR of 
AT1R mRNA. 
2.2. GAPDH, HuR and TIA-1 as mediators of stress responses 
The RNBPs identified in this thesis, i.e. GAPDH, HuR, and TIA-1, have been previously 
associated to various stress response pathways. All of them have been shown to 
posttranscriptionally regulate the expression of Cox-2, a central mediator of inflammatory 
responses (Dixon et al. 2003, Cok et al. 2003, Ikeda et al. 2012). Cox-2 is expressed in fatty 
streaks in arteries from both human and mice, and Cox-2 mRNA is upregulated in 
atherosclerotic plaques (Cipollone et al. 2004, Baldan et al. 2014). Another inflammatory 
cytokine, TNF , is also posttranscriptionally regulated by GAPDH, HuR, and TIA-1 
(Piecyk 2000, Dean et al. 2001, White et al. 2015). A number of CVD risk factors are 
associated with cellular events that have been proposed to involve TNF . These include 
cardiac remodeling (Zhao et al. 2008), vascular calcification (Masuda et al. 2013), 
inflammation (Li et al. 2005), and AT1R upregulation (Gurantz et al. 1999, Cowling et al. 
2002). These studies indicated that ER-stress-related pathways were involved in mediating 
TNF  effects. Further, HuR has been shown to promote, and TIA-1 to inhibit, the translation 
of apoptosis regulator, mitochondrial cytochrome c. The regulation is affected by ER stress 






(Kawai et al. 2006). Taken together, in addition to the posttranscriptional regulation of 
AT1R expression described in this thesis, GAPDH, HuR, and TIA-1 regulate a number of 
other factors associated with the development of CVDs. All in all, this suggests that 
GAPDH, HuR, and TIA-1 may form a posttranscriptional regulatory complex regulating 
several components of the CVD predisposing pathways. 
3. Challenges in studying the regulation of AT1R expression 
Currently the most common methods to study AT1R expression include measurement of 
AT1R mRNA expression by qPCR, measurement of the activation of downstream signaling 
molecules in response to Ang II, immunological assays using antibodies against AT1R, and 
measurement of membrane-expressed receptor by ligand-binding assay using radiolabeled 
Ang II. Of these, only the ligand-binding assay and immunological methods indicate actual 
changes in expression at the level of receptor protein. The changes in mRNA expression as 
measured by qPCR do not always correlate with changes in the protein expression. Changes 
in expression or activation of AT1R downstream signaling molecules in response to Ang II 
stimulation do not alone confirm alterations in AT1R expression. In contrast, they may 
simply indicate changes in AT1R signaling due to alteration in the balance of transcription 
variants or dimerization of the receptor (Warnecke et al. 1999, Martin et al. 2001, Martin et 
al. 2006, AbdAlla et al. 2000, AbdAlla et al. 2001a, AbdAlla et al. 2001b, Sungkaworn et 
al. 2013). While immunological methods are generally considered to be an established way 
to demonstrate actual changes at the protein level, they have proved to be challenging in the 
assessment of AT1R. Recent studies describe lack of specificity of the commercially 
available AT1R antibodies (Benicky et al. 2012, Herrera et al. 2013, Elliott et al. 2013). For 
this reason there is a need to generate more specific antibodies: either monoclonal or peptide 
antibodies. For the time being, ligand-binding assays may offer the most reliable approach 
to quantitate AT1R protein expression levels. 
In the current study, the proteins associated with AT1R 3’UTR were isolated by affinity 
purification and separated by SDS-PAGE. Thereafter the gels were either silver or 
coomassie-blue stained, the bands of interest were cut out, the proteins were treated with 






method, some AT1R 3’UTR-associated proteins may have escaped detection. Affinity 
purification relies on synthetic RNA probes consisting of only the 3’UTR. This may have 
an impact on the formation of the RNA secondary structures, like looping, affecting protein 
binding. Moreover, the silver and coomassie blue stainings are adequate techniques to detect 
abundantly-associated proteins, whereas proteins binding to lesser extent or only under 
specific conditions may remain undetected even when using a mass spectrometry approach. 
The use of GAPDH as a loading control or housekeeping gene in experimental setups should 
be considered carefully, especially in experiments using oxidative conditions. As shown in 
Study I, H2O2 decreased GAPDH expression. This is in line with a previous study showing 
reduced half-life of GAPDH due to H2O2-mediated oxidation (Sukhanov et al. 2006). In 
addition, the use of GAPDH for normalization of data has been questioned before in a study 
showing increased GAPDH mRNA expression during atherogenesis (Hiltunen et al. 1995). 
These observations combined with the multiple known functions of GAPDH in various 
cellular events makes its use as an experimental control questionable. If GAPDH expression 
is affected, the results will be incorrect when normalized against it. Therefore the use of 
multiple controls or total protein staining for western blots should be considered for more 
reliable normalization of data (Vandesompele et al. 2002, de Jonge et al. 2007, Gürtler et 
al. 2013, Li and Shen 2013). 
An additional technical caveat may come from recent studies proposing that AT1R mRNA 
expression may be differentially regulated in different cell types or tissues. An insulin-
resistant rat model with increased plasma insulin levels showed increased AT1R expression 
in thoracic arteries, in line with the results from Study II. However, the AT1R expression in 
the abdominal arteries was unchanged, suggesting that the regulatory mechanisms of AT1R 
may differ even in closely-connected areas (Karpe et al. 2012). In another study by Gao et 
al. (2014), AT1R mRNA localized into SGs in HeLa cells, which is opposite to observations 
from Study III where AT1R mRNA escaped sequestration to SGs in VSMCs. This suggests 
that AT1R regulation may be cell-type specific. This also raises the question of using 
immortalized cell lines as experimental models. While they are easy to work with, they 
differ from normal diploid cells significantly. Most of the immortalized cell lines have 
severe changes in their karyotypes (www.atcc.org/). As such, the results should be 














Cardiovascular diseases (CVDs), including hypertension and atherosclerosis, constitute the 
leading cause of death and disability globally. CVDs are multifactorial diseases and several 
underlying mechanisms contribute to the risk of their development. AT1R is a central 
component of the renin-angiotensin system regulating the blood pressure as well as body 
fluid and electrolyte homeostasis. AT1R signaling also results in the generation of ROS that 
contribute to various deleterious cellular effects in CVDs. The role of AT1R in the 
development of CVDs is supported by the beneficial effects achieved by pharmacological 
inhibition of AT1R function. 
AT1R expression is regulated at multiple levels but the underlying mechanisms are not 
completely understood. The aim of this thesis was to identify novel RNBPs involved in the 
posttranscriptional regulation of AT1R expression. The 3’UTR of AT1R mRNA has 
emerged as a key regulatory element that posttranscriptionally regulates AT1R expression 
via trans-acting factors. During the course of this study, three novel RNBPs regulating 
AT1R expression via AT1R 3’UTR were identified: GAPDH, HuR, and TIA-1. While 
certain aspects of the individual roles of these three trans-acting factors 
posttranscriptionally regulating AT1R mRNA expression have been delineated in the 
present thesis, the details of their cooperation and interactions remain to be resolved. 
Under normal physiological conditions, both GAPDH and TIA-1 repress AT1R expression 
while HuR increases it. GAPDH inhibits the translation of AT1R mRNA while stabilizing 
the mRNA transcript. Similarly, TIA-1 suppress AT1R protein expression while having a 
positive effect on the mRNA levels. On the other hand, HuR stabilizes the AT1R mRNA 
leading to increased AT1R protein expression. Together with previous studies, these 
findings further strengthen the role of AT1R 3’UTR as an important regulatory element in 
AT1R expression. The 3’UTR of AT1R is a target for a number of both positive and 
negative trans-acting factors. This proposes that the expression of AT1R may be controlled 







The expression of AT1R is affected by various pathophysiological stimuli by regulating the 
association of trans-acting factors to the 3’UTR. Under oxidizing conditions, overall 
GAPDH expression is reduced and GAPDH dissociated from the AT1R mRNA. This 
releases AT1R mRNA from the translational suppression of GAPDH leading to increased 
AT1R protein expression. The insulin-induced upregulation of AT1R expression is 
mediated by HuR via AT1R 3’UTR. Insulin stimulation increases the nucleocytoplasmic 
translocation of HuR. This is accompanied by increased association of HuR with AT1R 
3’UTR, promoting the positive impact of HuR on AT1R expression. During ER stress, 
caused by ER Ca2+ deprivation, AT1R mRNA escapes the sequestration to translationally 
silenced SGs. ER stress releases the SG component TIA-1 from AT1R mRNA, whereafter 
unbound TIA-1 is directed to SGs releasing AT1R mRNA from TIA-1 suppression. As a 
result, the relative AT1R protein expression is increased during ER stress. 
Taken together, the results of this thesis suggest that insulin resistance, ROS, and ER stress 
may contribute to the development of CVDs by affecting posttrancriptional regulation of 
AT1R expression. Better understanding of the complex network of posttranscriptional 
regulation of AT1R expression may create new possibilities to assist in the investigation of 
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